

# Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms

This manuscript ([permalink](#)) was automatically generated from [greenelab/phenoplier\\_manuscript@9c36e6d](mailto:greenelab/phenoplier_manuscript@9c36e6d) on September 12, 2022.

## Authors

---

- **Milton Pividori**  
 [0000-0002-3035-4403](#) ·  [miltondp](#) ·  [miltondp](#)  
Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA ·  
Funded by The Gordon and Betty Moore Foundation GBMF 4552; The National Human Genome Research Institute (R01 HG010067); The National Human Genome Research Institute (K99HG011898)
- **Sumei Lu**  
Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
- **Binglan Li**  
 [0000-0002-0103-6107](#)  
Department of Biomedical Data Science, Stanford University, Stanford, CA, USA
- **Chun Su**  
 [0000-0001-6388-8666](#) ·  [sckinta](#)  
Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
- **Matthew E. Johnson**  
Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
- **Wei-Qi Wei**  
Vanderbilt University Medical Center
- **Qiping Feng**  
 [0000-0002-6213-793X](#)  
Vanderbilt University Medical Center
- **Bahram Namjou**  
Cincinnati Children's Hospital Medical Center
- **Krzysztof Kiryluk**  
 [0000-0002-5047-6715](#) ·  [kirylukk](#)  
Department of Medicine, Division of Nephrology, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York

- **Iftikhar Kullo**

Mayo Clinic

- **Yuan Luo**

Northwestern University

- **Blair D. Sullivan**

School of Computing, University of Utah, Salt Lake City, UT, USA

- **Benjamin F. Voight**

 [0000-0002-6205-9994](#) ·  [bvoight](#) ·  [bvoight28](#)

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

- **Carsten Skarke**

 [0000-0001-5145-3681](#) ·  [CarstenSkarke](#)

Institute for Translational Medicine and Therapeutics, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

- **Marylyn D. Ritchie**

 [0000-0002-1208-1720](#) ·  [MarylynRitchie](#)

Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

- **Struan F.A. Grant**

 [0000-0003-2025-5302](#) ·  [STRUANGRANT](#)

Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA; Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA

- **Casey S. Greene** 

 [0000-0001-8713-9213](#) ·  [cgreene](#) ·  [GreeneScientist](#)

Center for Health AI, University of Colorado School of Medicine, Aurora, CO 80045, USA; Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO 80045, USA · Funded by The Gordon and Betty Moore Foundation (GBMF 4552); The National Human Genome Research Institute (R01 HG010067); The National Cancer Institute (R01 CA237170)

✉ — Correspondence possible via [GitHub Issues](#) or email to Casey S. Greene  
<casey.s.greene@cuanschutz.edu>.

# Abstract

---

Understanding how dysregulated transcriptional processes result in tissue-specific pathology requires a mechanistic interpretation of expression regulation across different cell types. It has been shown that this insight is key for the development of new therapies. These mechanisms can be identified with transcriptome-wide association studies (TWAS), which have represented a significant step forward to test the mediating role of gene expression in GWAS associations. However, it is hard to disentangle causal cell types using eQTL data alone, and other methods generally do not use the large amounts of publicly available RNA-seq data. Here we introduce PhenoPLIER, a polygenic approach that maps both gene-trait associations and pharmacological perturbation data into a common latent representation for a joint analysis. This representation is based on modules of genes with similar expression patterns across the same tissues. We observed that diseases were significantly associated with gene modules expressed in relevant cell types, and our approach was accurate in predicting known drug-disease pairs and inferring mechanisms of action. Furthermore, using a CRISPR screen to analyze lipid regulation, we found that functionally important players lacked TWAS associations but were prioritized in phenotype-associated modules by PhenoPLIER. By incorporating groups of co-expressed genes, PhenoPLIER can contextualize genetic associations and reveal potential targets within associated processes that are missed by single-gene strategies.

## Introduction

---

**NOTES:** - start talking about gene modules - then say that gene modules are expressed in specific tissues/cell types - and then connect with the rest

Human diseases have tissue-specific etiologies and manifestations [1,2,3]. In this context, determining how genes influence these complex phenotypes requires mechanistically understanding expression regulation across different cell types [4,5,6], which in turn should lead to improved treatments [7,8]. Previous studies have described regulatory DNA elements, including chromatin-state annotations [9,10], high-resolution enhancers [11,12], DNase I hypersensitivity maps [5], and genetic effects on gene expression across different tissues [4]. Integrating functional genomics data and GWAS data [13] has improved the identification of these transcriptional mechanisms that, when dysregulated, commonly result in tissue- and cell lineage-specific pathology.

Given the availability of gene expression data across several tissues [4,14,15,16], a popular approach to identify these biological processes is the transcription-wide association study (TWAS), which integrates expression quantitative trait loci (eQTLs) data to provide a mechanistic interpretation for GWAS findings. TWAS relies on testing whether perturbations in gene regulatory mechanisms mediate the association between genetic variants and human diseases [17,18,19,20]. However, TWAS has not reliably detected tissue-specific effects because eQTLs are commonly shared across tissues [21,22]. This sharing makes it challenging to identify the tissue or tissues that are etiologically relevant. Existing methods that connect GWAS findings with gene expression data can infer disease-relevant tissues and cell types [22,23,24,25,26,27], but they generally rely on small sets of expression data compared with the total number of RNA-seq samples that are increasingly available [14,15]. Moreover, widespread gene pleiotropy across complex traits reveals the highly interconnected nature of transcriptional networks [28,29], where potentially all genes expressed in disease-relevant cell types have a non-zero effect [30,31]. Consequently, this complicates the interpretation of genetic effects and hampers translational efforts.

We propose PhenoPLIER, a polygenic approach that infers how groups of functionally-related genes influence complex traits, and how pharmacological perturbations affect these genes' activity to exert their effects. The approach maps both gene-trait associations and drug-induced transcriptional


responses into a common representation for a joint analysis. For this, we integrated more than 4,000 gene-trait associations (using TWAS from PhenomeXcan [32]) and transcriptional profiles of drugs (LINCS L1000 [33]) into a low-dimensional space learned from public gene expression data on tens of thousands of RNA-seq samples (recount2 [14,34]). We used a latent representation defined by a computational approach [35] that learns recurrent gene co-expression patterns with certain sparsity constraints and preferences for those that align with prior knowledge (pathways). This low-dimensional space comprised features representing groups of genes (gene modules) with coordinated expression across different tissues and cell types. When mapping gene-trait associations to this reduced expression space, we observed that diseases were significantly associated with gene modules expressed in relevant cell types, such as hypothyroidism with T cells and thyroid, corneal endothelial cells with keratometry measurements, hematological assays on specific blood cell types, plasma lipids with adipose tissue, and neuropsychiatric disorders with different brain cell types. Moreover, since we rely on a large and heterogeneous RNA-seq dataset, we were also able to identify modules associated with cell types under specific stimuli or disease states. We replicated gene module associations with cardiovascular and autoimmune diseases in the Electronic Medical Records and Genomics (eMERGE) network phase III [36,37]. Furthermore, we performed a CRISPR screen to analyze lipid regulation in HepG2 cells and observed more robust trait associations with modules than with individual genes, even when single genes known to be involved in lipid metabolism did not reach genome-wide significance. Compared to a single-gene approach, our module-based method also better predicted FDA-approved drug-disease links by capturing tissue-specific pathophysiological mechanisms linked with the mechanism of action of drugs (e.g., niacin with cardiovascular traits via a known immune mechanism), suggesting that modules may provide a better means to examine drug-disease relationships than individual genes. Finally, exploring the phenotype-module space also revealed stable trait clusters associated with relevant tissues, including a complex branch involving lipids with cardiovascular, autoimmune, and neuropsychiatric disorders. In summary, instead of considering single genes associated with different complex traits, PhenoPLIER incorporates groups of genes that act together to carry out different functions in specific cell types. This improves robustness to detect and interpret genetic associations, and here we show how it can prioritize alternative and potentially more promising candidate targets when important single gene associations are not detected. The approach represents a conceptual shift in the interpretation of genetic studies, and has the potential to extract mechanistic insight from statistical associations to enhance the understanding of complex diseases and their therapeutic modalities.

## Results

---

### **PhenoPLIER: an integration framework based on gene co-expression patterns**

**NOTES:** - in methods I refer to PhenomeXcan as discovery cohort - and eMERGE as replication cohort



**Figure 1: Schematic of the PhenoPLIER framework.** **a)** High-level schematic of PhenoPLIER (a gene module-based method) in the context of TWAS (single-gene) and GWAS (genetic variants). PhenoPLIER integrates groups of genes co-expressed in specific cell types (gene modules) with gene-trait and gene-drug associations. **b)** The integration consists of projecting gene-trait/gene-drug associations from PhenomeXcan/LINCS L1000 (bottom) to a latent space based on gene modules (represented by latent variables/LVs) from MultiPLIER (top). The process generates matrix  $\hat{M}$ , where each trait/drug is now described by LVs (only traits are shown). **c)** LV603, termed as a neutrophil signature in the original MultiPLIER study, was associated in PhenoPLIER with neutrophil counts and other white blood cells (bottom, showing the top 10 traits for LV603). Genes in LV603 were expressed in relevant cell types (top). PBMC: peripheral blood mononuclear cells; mDCs: myeloid dendritic cells.


PhenoPLIER combines TWAS and drug-induced transcriptional responses with gene co-expression patterns by projecting gene-trait and gene-drug associations onto a latent gene expression representation (Figure 1). We used PhenomeXcan [32], a TWAS resource for the UK Biobank [38] and other cohorts with 4,091 different diseases and traits, and the transcriptional responses to small molecule perturbations from LINCS L1000 [33] comprising 1,170 compounds. We obtained a latent gene expression representation from MultiPLIER [34], an unsupervised learning approach applied to recount2 [14] – a uniformly-curated collection of transcript-level gene expression quantified by RNA-seq in a large, diverse set of samples collected across a range of disease state, cell types differentiation stages, and various stimuli (Methods). MultiPLIER extracted 987 latent variables (LV) by optimizing data reconstruction but also the alignment of LVs with prior knowledge/pathways (Methods). Each LV or gene module represents a group of weighted genes expressed together in the same tissues and cell types as a functional unit. Since LVs might represent a functional set of genes regulated by the same transcriptional program [39,40], we conjecture that the projection of TWAS and pharmacologic perturbations data into this latent space could provide context for their interpretation. PhenoPLIER converts gene associations to an LV score: all genes' standardized effect sizes for a trait (from TWAS) or differential expression values for a drug (from pharmacologic perturbation data) are multiplied by the LV genes' weights and summed, producing a single value. This process links different traits and drugs to LVs representing cell types and tissues, even at specific developmental stages or under distinct stimuli. Examining these LVs is possible because the MultiPLIER's models link to samples, which may be annotated for experimental conditions (represented by matrix  $B$  in Figure 1 b, top) in which genes in an LV are expressed. To further analyze LV-trait associations, we adapted the gene-property approach from MAGMA [41] to compute an LV-trait  $p$ -value by fitting a regression model with LV weights as predictors of a trait's gene associations. Thus PhenoPLIER allows the user to address specific questions, namely: do disease-associated genes belong to modules expressed in specific tissues and cell types? Are these cell type-specific modules associated with different diseases (thus, potentially representing a “network pleiotropy” example from an omnigenic point of view [30])?

Is there a subset of module's genes that is closer to the definition of "core" genes (i.e., directly affecting the trait with no mediated regulation of other genes [31]) and thus represent alternative and potentially better candidate targets? Are drugs perturbing these transcriptional mechanisms, and if so, can they suggest potential mechanisms of action?

In the original MultiPLIER study, the authors reported that one of the latent variables, identified as LV603, was associated with a known neutrophil pathway and highly correlated with neutrophil count estimates from whole blood RNA-seq profiles [42]. We analyzed LV603 using PhenoPLIER (Figure 1 c) and found that 1) neutrophil counts and other white blood cell traits were ranked among the top 10 traits out of 4,091 (Figure 1 c, bottom) and significantly associated with this LV (Supplementary Table 3) when using the gene-property approach, and 2) LV603's genes were expressed in highly relevant cell types (Figure 1 c, top). These results suggested that groups of functionally related and co-expressed genes tend to correspond to groups of trait-associated genes. Thus, the gene expression space (which has no GTEx samples) and the TWAS space (with gene models trained using GTEx v8) contained shared patterns, and the approach can link transcriptional mechanisms from large and diverse dataset collections to complex traits.

## **LVs link genes that alter lipid accumulation with relevant traits and tissues**

Our first experiment attempted to answer whether genes in a disease-relevant LV could represent potential therapeutic targets. For this, the first step was to obtain a set of genes strongly associated with a phenotype of interest. Therefore, we performed a fluorescence-based CRISPR-Cas9 in the HepG2 cell line and identified 462 genes associated with lipid regulation (Methods). From these, we selected two high-confidence gene-sets that either caused a decrease or increase of lipids: a lipids-decreasing gene-set with eight genes: *BLCAP*, *FBXW7*, *INSIG2*, *PCYT2*, *PTEN*, *SOX9*, *TCF7L2*, *UBE2J2*; and a lipids-increasing gene-set with six genes: *ACACA*, *DGAT2*, *HILPDA*, *MBTPS1*, *SCAP*, *SRPR* (Supplementary File 1).




**Figure 2: Tissues and traits associated with a gene module related to lipid metabolism (LV246).** **a)** Top cell types/tissues where LV246's genes are expressed in. Values in the *y*-axis come from matrix **B** in the MultiPLIER models (Figure 1 b, see Methods). In the *x*-axis, cell types/tissues are sorted by the maximum sample value. **b)** Gene-trait associations (S-MultiXcan; threshold at  $-\log(p)=10$ ) and colocalization probability (fastENLOC) for the top traits in LV246. The top 40 genes in LV246 are shown, sorted by their LV weight (matrix **Z**), from largest (the top gene *SCD*) to smallest (*FAR2*). *DGAT2* and *ACACA*, in boldface, are two of the six high-confidence genes in the lipids-increasing gene-set from the CRISPR-screen. Cardiovascular-related traits are in boldface. SGBS: Simpson Golabi Behmel Syndrome; CH<sub>2</sub>DB: CH<sub>2</sub> groups to double bonds ratio; HDL: high-density lipoprotein; RCP: locus regional colocalization probability.

Next, we analyzed all 987 LVs using Fast Gene Set Enrichment Analysis (FGSEA) [43], and found 15 LVs nominally enriched (unadjusted  $P < 0.01$ ) with these lipid-altering gene-sets (Supplementary Tables 5 and 6). Among those with reliable sample metadata, LV246, the top LV associated with the lipids-increasing gene-set, contained genes mainly co-expressed in adipose tissue (Figure 2 a), which plays a key role in coordinating and regulating lipid metabolism. Using the gene-property analysis method, we found that gene weights for this LV were predictive of gene associations for plasma lipids and high cholesterol (Supplementary Table 8). Two high-confidence genes from our CRISPR screening, *DGAT2* and *ACACA*, are responsible for encoding enzymes for triglycerides and fatty acid synthesis and were among the highest-weighted genes of LV246 (Figure 2 b, in boldface). However, in contrast to other members of this LV, *DGAT2* and *ACACA* were not strongly associated nor colocalized with any of the cardiovascular-related traits and thus would not have been prioritized by TWAS alone; other members of LV246, such as *SCD*, *LPL*, *FADS2*, *HMGCR*, and *LDLR*, were instead significantly associated and colocalized with lipid-related traits. This lack of association/cocolocalization of two high-confidence genes from our CRISPR-screen might be explained from an omnigenic point of view [31]. Assuming that the TWAS models for *DGAT2* and *ACACA* capture all common *cis*-eQTLs (the only genetic component of gene expression that TWAS can capture) and there are no rare *cis*-eQTLs, these two genes might represent “core” genes (i.e., they directly affect the trait with no mediated regulation of other genes), and many of the rest in the LV are “peripheral” genes that *trans*-regulate them. These results suggested that our LV-based approach can contextualize genetic associations and prioritize alternative therapeutic targets, mainly when TWAS cannot detect them or hits are not druggable.

## PhenoPLIER with LVs predicts drug-disease pairs better than single genes

We next determined the extent to which substituting LVs in place of individual genes predicted known treatment-disease relationships. For this, we used the transcriptional responses to small molecule perturbations profiled in LINCS L1000 [33], which were further processed and mapped to DrugBank IDs [44,45,46]. Based on an established drug repurposing strategy that matches reversed transcriptome patterns between genes and drug-induced perturbations [47,48], we adopted a previously described framework that uses imputed transcriptomes from TWAS to prioritize drug candidates [49]. For this, we computed a drug-disease score by calculating the negative dot product between the  $z$ -scores for a disease (from TWAS) and the  $z$ -scores for a drug (from LINCS) across sets of genes of different size (see Methods). Therefore, a large score for a drug-disease pair indicated that a higher (lower) predicted expression of disease-associated genes are down (up)-regulated by the drug, thus predicting a potential treatment. Similarly, for the LV-based approach, we estimated how pharmacological perturbations affected the gene module activity by projecting expression profiles of drugs into our latent representation (Figure 1 b). We used a manually-curated gold standard set of drug-disease medical indications [45,50] for 322 drugs across 53 diseases to evaluate the prediction performance.




**Figure 3: Drug-disease prediction performance for gene-based and module-based approaches.** The receiver operating characteristic (ROC) (left) and the precision-recall curves (right) for a gene-based and our module-based approach. AUC: area under the curve; AP: average precision.

The gene-trait associations and drug-induced expression profiles projected into the latent space represent a compressed version of the entire set of results. Despite this information loss, the LV-based method outperformed the gene-based one with an area under the curve of 0.632 and an average precision of 0.858 (Figure 3). The prediction results suggested that this low-dimensional space captures biologically meaningful patterns that can link pathophysiological processes with the mechanism of action of drugs.

We examined a specific drug-disease pair to determine whether the LVs driving the prediction were biologically plausible. Nicotinic acid (niacin) is a B vitamin widely used clinically to treat lipid disorders, although there is controversy on its clinical utility to prevent cardiovascular disease [51,52,53]. Niacin exerts its effects on multiple tissues, although its mechanisms are not well understood [54,55,56,57]. This compound can increase high-density lipoprotein (HDL) by inhibiting an HDL catabolism receptor in the liver. Niacin also inhibits diacylglycerol acyltransferase-2 (DGAT2), which decreases the production of low-density lipoproteins (LDL) by modulating triglyceride synthesis in hepatocytes or by inhibiting adipocyte triglyceride lipolysis [54]. Niacin was one of the drugs in the gold standard set indicated for atherosclerosis (AT) and coronary artery disease (CAD). We observed that this compound

was predicted by the gene-based and LV-based approach as a medical indication for coronary artery disease (CAD), with scores above the mean (0.51 and 0.96, respectively). For AT, the LV-based approach predicted niacin as a therapeutic drug with a score of 0.52, whereas the gene-based method assigned a negative score of -0.01 (below the mean). Since LVs represent interpretable features associated with specific cell types, we analyzed which LVs were positively contributing to these predictions (i.e., with an opposite direction between niacin and the disease). Notably, LV246 (Figure 2), expressed in adipose tissue and liver and associated with plasma lipids and high cholesterol (Supplementary Table 8), was the 16th most important module in the prediction of niacin as a therapeutic drug for AT. Besides the gold standard set, LV246 was among the top modules for other cardiovascular diseases, such as ischaemic heart disease (wide definition, 15th module) and high cholesterol (7th module).



**Figure 4: Top cell types/tissues where LV116's genes are expressed in.** Values in the *y*-axis come from matrix **B** in the MultiPLIER models (Figure 1 b). In the *x*-axis, cell types/tissues are sorted by the maximum sample value. The figure shows a clear immune response with cell types under different stimuli. MS: multiple sclerosis; HSV: treated with herpes simplex virus; WNV: infected with West Nile virus; IFNa: treated with interferon-alpha; HMDM: human peripheral blood mononuclear cell-derived macrophages; Salm: infected with *Salmonella typhimurium*; Yers: infected with *Yersinia pseudotuberculosis*; ISM: Interferon Signature Metric; SLE: Systemic lupus erythematosus.

The analysis of other top niacin-contributing LVs across different cardiovascular diseases revealed additional mechanisms of action. For example, *GPR109A/HCAR2* encodes a G protein-coupled high-affinity niacin receptor in adipocytes and immune cells, including monocytes, macrophages, neutrophils and dendritic cells [58,59]. It was initially thought that the antiatherogenic effects of niacin were solely due to inhibition of lipolysis in adipose tissue. However, it has been shown that nicotinic acid can reduce atherosclerosis progression independently of its antidiabetic activity through the activation of *GPR109A* in immune cells [60], thus boosting anti-inflammatory processes [61]. In addition, flushing, a common adverse effect of niacin, is also produced by the activation of GPR109A in Langerhans cells (macrophages of the skin). This alternative mechanism for niacin could have been hypothesized by examining the cell types where the top-contributing modules are expressed: for instance, LV116 and LV931 (Figure 4, Supplementary Figure 13, and Supplementary Tables 10 and 11) were the top two modules for AT, with a strong signature in monocytes, macrophages, neutrophils, dendritic cells, among others. In Figure 4, it can be seen that LV116's genes are expressed as an


immune response when these cell types are under different stimuli, such as diarrhea caused by different pathogens [62], samples from multiple sclerosis or systemic lupus erythematosus [63,64], or infected with different viruses (such as herpes simplex [65], West Nile virus [66], *Salmonella typhimurium* [67], among others). These three LVs (LV246, LV116 and LV931) were among the top 20 modules contributing to the niacin prediction across different cardiovascular traits (Table 1). Given the current controversy around this compound and its effect on cardiovascular disease, our approach may help to better understand different pathophysiological mechanisms linked with the mechanism of action of niacin.

**Table 1:** LVs among the top 20 contributors of prediction of niacin for five cardiovascular diseases. “Heart attack, angina, stroke or hypertension” refers to the UK Biobank data-field 6150. GWAS sample size: Atherosclerosis (361,194 in total and 566 cases), Chronic ischaemic heart disease (361,194 in total and 12,769 cases), Heart attack, angina, stroke or hypertension (360,420 in total and 253,565 cases), Ischaemic heart disease/wide definition (361,194 in total and 20,857 cases), High cholesterol/self-reported (361,141 in total and 43,957 cases).

LV	Cell type	Disease
LV116	Immune cells, skin	Atherosclerosis (ICD10 I70)
		Chronic ischaemic heart disease (ICD10 I25)
		Heart attack, angina, stroke or hypertension
		Ischaemic heart disease (wide definition)
LV931	Immune cells	Atherosclerosis (ICD10 I70)
		Heart attack, angina, stroke or hypertension
		Ischaemic heart disease (wide definition)
LV246	Adipose tissue, liver	Atherosclerosis (ICD10 I70)
		High cholesterol (self-reported)
		Ischaemic heart disease (wide definition)

The LV-based method was able to integrate different data types to provide an interpretable approach for drug repositioning research based on genetic studies. Additionally, our approach could also be helpful to understand better the mechanism of pharmacological effect of known or experimental drugs. For example, LV66, one of the top LVs affected by niacin (Supplementary Figure 14) was mainly expressed in ovarian granulosa cells. This compound has been very recently considered as a potential therapeutic for ovarian diseases [68,69], as it was found to promote follicle growth and inhibit granulosa cell apoptosis in animal models. Our LV-based approach could be helpful to generate novel hypotheses to evaluate potential mechanisms of action, or even adverse effects, of different drugs.


## LV projections reveal trait clusters with shared transcriptomic properties



**Figure 5: Cluster analysis on traits using the latent gene expression representation.** **a)** The projection of TWAS results on  $n=3,752$  traits into the latent gene expression representation is the input data to the clustering process. A linear (PCA) and non-linear (UMAP) dimensionality reduction techniques were applied to the input data, and the three data versions were processed by five different clustering algorithms. These algorithms derive partitions from the data using different sets of parameters (such as the number of clusters), leading to an ensemble of 4,428 partitions. Then, a distance matrix is derived by counting how many times a pair of traits were grouped in different clusters across the ensemble. Finally, a consensus function is applied to the distance matrix to generate consolidated partitions with different numbers of clusters (from 2 to  $\sqrt{n} \approx 60$ ). These final solutions were represented in the clustering tree (Figure 6). **b)** The clusters found by the consensus function were used as labels to train a decision tree classifier on the original input data, which detects the LVs that better differentiate groups of traits.

The previous results suggested that the compression into  $\hat{\mathbf{M}}$  increases the signal-to-noise ratio. Thus, we analyzed  $\hat{\mathbf{M}}$  to find groups of traits that were affected by the same transcriptional processes. To identify relationships that were robust to the selection of a specific clustering algorithm (each of which makes particular assumptions about the structure of data), we employed a consensus clustering approach. Therefore, we applied different methods with varying sets of parameters and later combined these into a consolidated solution (Methods). Our clustering pipeline generated 15 final consensus clustering solutions with 5 to 29 clusters (Supplementary Figure 15). Instead of selecting a


specific number of clusters, we used a clustering tree [70] (Figure 6) to examine stable groups of traits across multiple resolutions. To understand which latent variables differentiated the group of traits, we trained a decision tree classifier on the input data  $\hat{\mathbf{M}}$  using the clusters found as labels.



**Figure 6: Clustering tree using multiple resolutions for clusters of traits.** Each row represents a partition/grouping of the traits, and each circle is a cluster from that partition. The number of clusters goes from 5 to 29. Arrows indicate how traits in one cluster move across clusters from different partitions. Most of the clusters are preserved across different resolutions, showing highly stable solutions even with independent runs of the clustering algorithm. RDW: red cell (erythrocyte) distribution width; BMI: body mass index; WC: waist circumference; HC: hip circumference; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; HTN: Hypertension; IBD: inflammatory bowel disease; SCZ: Schizophrenia; CAD: Coronary artery disease; AD: Alzheimer's disease; *Descriptions of traits by cluster ID (from left to right):* 12: also includes lymphocyte count and allergies such as allergic rhinitis or eczema; 4: includes reticulocyte count and percentage, immature reticulocyte fraction, and high light scatter reticulocytes count and percentage; 2: includes mean corpuscular volume, mean corpuscular hemoglobin, mean reticulocyte volume, mean spheroid cell volume; 5: includes erythrocyte count, hemoglobin concentration, and hematocrit percentage; 20: also includes weight, waist and hip circumference; 18: also includes body impedance measures and ankle spacing width; 19: also includes basal metabolic rate; 1: includes platelet count, crit, mean volume, and distribution width; 13: diabetes refers to age when diabetes was first diagnosed; 25: also includes vascular problems such as angina, deep vein thrombosis (DVT), intraocular pressure, eye and mouth problems, pulse rate, hand-grip strength, several measurements of physical activity, jobs involving heavy physical work, types of transport used, intake of vitamin/mineral supplements, and various types of body pain and medications for pain relief; 21: also includes attention deficit hyperactivity disorder (ADHD), number of years of schooling completed, bone density, and intracranial volume measurement; 28: includes diabetes,

gout, arthrosis, and respiratory diseases (and related medications such as ramipril, allopurinol, and lisinopril), urine assays, female-specific factors (age at menarche, menopause, first/last live birth), and several environmental/behavioral factors such as intake of a range of food/drink items including alcohol, time spent outdoors and watching TV, smoking and sleeping habits, early-life factors (breastfed as a baby, maternal smoking around birth), education attainment, psychological and mental health, and health satisfaction; 11: also includes fasting blood glucose and insulin measurement; 16: lipids include high and low-density lipoprotein (HDL and LDL) cholesterol, triglycerides, and average number of methylene groups per a double bond; 14: includes myocardial infarction, coronary atherosclerosis, ischaemic heart disease (wide definition); 7: includes monocyte count and percentage; 24: includes lymphocyte count and percentage; 9: includes neutrophil count, neutrophil+basophil count, neutrophil+eosinophil count, granulocyte count, leukocyte count, and myeloid cell count; 3: includes eosinophil count, eosinophil percentage, and eosinophil+basophil count.

We found that phenotypes were grouped into five clear branches (Figure 6). These were 0) a “large” branch that includes most of the traits subdivided only starting at  $k=16$  (with asthma, subjective well-being traits, and nutrient intake clusters), 1) heel bone-densitometry measurements, 2) hematological assays on red blood cells, 3) physical measures, including spirometry and body impedance, and anthropometric traits with fat-free and fat mass measures in separate sub-branches, and 4) a “complex” branch including keratometry measurements, assays on white blood cells and platelets, skin and hair color traits, autoimmune disorders (type 1 diabetes, psoriasis, hyper/hypothyroidism, rheumatoid arthritis, systemic lupus erythematosus, celiac disease), and cardiovascular diseases (hypertension, coronary artery disease, myocardial infarction, hypercholesterolemia, and other cardiovascular-related traits such hand-grip strength [71], and environmental/behavioral factors such as physical activity and diet) (See Supplementary Files 2-6 for clustering results). Within these branches, results were relatively stable. The same traits were often clustered together across different resolutions, even with the consensus algorithm using random initializations at each level. Arrows between different clusters show traits moving from one group to another across different resolutions. This mainly happens between clusters within the “complex” branch, and between clusters from the “large” branch to the “complex” branch. We would expect that continuing to explore higher dimensionalities would result in further subdivisions of these large groupings. This behavior was expected since complex diseases are usually associated with shared genetic and environmental factors and are thus hard to categorize into a single cluster. We would also expect that exploring solutions with a larger number of clusters would result in further subdivisions of these large groupings.



**Figure 7: Cluster-specific and general transcriptional processes associated with disease.** The plot shows a submatrix of  $\hat{M}$  for the main trait clusters at  $k=29$ , considering only LVs (rows) that are well-aligned with at least one pathway. Standardized values from -5 (lighter color) to 16 (darker color).

Next, we analyzed which LVs were driving these clusters of traits. We trained decision tree classifiers on the input data (Figure 5) using each cluster at  $k=29$  (bottom of Figure 6) as labels (see Methods). This yielded for each cluster the top LVs, where several of them were well-aligned to existing pathways (Figure 7), and others were novel and expressed in relevant tissues (Supplementary Figure 16). In Figure 7, it can be seen that some LVs were highly specific to certain types of traits, while others were associated with a wide range of different phenotypes, thus potentially involved in more general biological functions. For example, LVs such as LV928 and LV30, which were well-aligned to early progenitors of the erythrocytes lineage [72] (Supplementary Tables 13 and 16), were predominantly expressed in early differentiation stages of erythropoiesis (Supplementary Figures 17 and 18) and strongly associated with different assays on red blood cells ( $FDR < 0.05$ ; Supplementary Tables 14, 15, and 18). In contrast, other LVs were highly specific, such as LV730, which is expressed in thrombocytes from different cancer samples (Supplementary Figures 19 and Supplementary Table 19), and strongly associated with hematological assays on platelets ( $FDR < 2e-4$ , Supplementary Table 20); or LV598, whose genes were expressed in corneal endothelial cells (Supplementary Figures 20 and Supplementary Table 22) and associated with keratometry measurements ( $FDR < 4e-05$ ; Supplementary Table 23).

The autoimmune diseases sub-branch also had significant LVs associations expressed in relevant cell types. LV844 was the most strongly associated gene module with autoimmune disorders in both PhenomeXcan ( $FDR < 7e-16$ ; Supplementary Tables 26) and eMERGE ( $FDR < 2e-6$ , 27), and was expressed in a wide range of cell types, including blood, breast organoids, myeloma cells, lung

fibroblasts, and different cell types from the brain (Supplementary Figures 21 and Supplementary Table 25). LV155 was strongly expressed in the thyroid (Supplementary Figures 22 and Supplementary Table 28) and significantly associated with hypothyroidism both in PhenomeXcan (FDR < 0.05, Supplementary Table 29) and eMERGE (FDR < 0.10, Supplementary Table 30). Other important LVs associated with autoimmunity in both PhenomeXcan and eMERGE were LV57, expressed in T cells (Supplementary Figure 23 and Supplementary Tables 31, 32, 33), and LV54, expressed in different soft tissue tumors, breast, lung, pterygia and epithelial cells (Supplementary Figure 24 and Supplementary Tables 34, 35, 36).

The cardiovascular sub-branch also exhibited significant associations. LV847 (Supplementary Figure 25 and Supplementary Table 37) was strongly associated with hypertension in PhenomeXcan (FDR < 2e-13, Supplementary Tables 38) and several cardiovascular diseases, type 1 diabetes, prostate cancer, and others in eMERGE (FDR < 0.05, Supplementary Table 39). LV847 was expressed in CD19 (B cells) (which are related to preeclampsia [73]), Jurkat cells (T lymphocyte cells), and cervical carcinoma cell lines (the uterus was previously reported to be linked to blood pressure through a potential hormonal pathway [74,75]). LV136 was aligned with known collagen formation and muscle contraction pathways (Supplementary Table 40), and it was associated with coronary artery disease (FDR < 2e-8), myocardial infarction (FDR < 6e-4) and keratometry measurements (FDR < 1e-7) in PhenomeXcan (Supplementary Tables 41), but with no strong associations in eMERGE (FDR < 0.20, Supplementary Table 42). This LV was expressed in a wide range of cell types, including fibroblasts, mesenchymal stem cells, osteoblasts, pancreatic stellate cells, cardiomyocytes, and adipocytes (Supplementary Figure 26). Lipids, clustered with chronotype and Alzheimer's disease, were significantly associated with several modules expressed mainly in brain cell types, including LV93 (Supplementary Figure 27 and Supplementary Tables 43, 44, 45), LV206 (Supplementary Figure 28 and Supplementary Tables 46, 47, 48), and LV260 (Supplementary Figure 29 and Supplementary Tables 49, 50 and 51). These modules were associated mainly with cardiovascular traits in eMERGE.

Within the cardiovascular sub-branch, we found neuropsychiatric and neurodevelopmental disorders such as Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). These disorders were previously linked to the cardiovascular system [76,77,78,79] and share several risk factors, including hypertension, high cholesterol, obesity, smoking, among others [80,81]. In our results, however, these diseases were grouped by potentially shared transcriptional processes expressed in specific tissues/cell types. Alzheimer's disease, for example, was significantly associated with LV21 in PhenomeXcan (FDR < 2e-19, Supplementary Table 53) and with LV5 (FDR < 3e-3, Supplementary Table 56). LV21 was strongly expressed in a variety of soft tissue sarcomas, monocytes/macrophages (including microglia from cortex samples), and aortic valves (Supplementary Figure 30 and Supplementary Table 52). This LV was also associated with lipids: LDL cholesterol (FDR < 1e-4) and triglycerides (FDR < 0.02). As discussed previously, macrophages play a key role in the reverse cholesterol transport and thus atherogenesis [82], and lipid metabolism in microglia has been recently identified as an important factor in the development of neurodegenerative diseases [83]. On the other hand, LV5 was expressed in breast cancer and brain glioma samples, microglia (cortex), liver, and kidney, among other cell types (Supplementary Figure 31 and Supplementary Table 55). In addition to lipids, LV5 was also associated with depression traits from the UK Biobank (FDR < 0.05, Supplementary Table 56). Since Alzheimer's disease was not present in eMERGE, we could not replicate this association. ADHD was the only significantly associated trait for LV434 (FDR < 6e-3) (Supplementary Table 59), which was expressed in breast cancer and glioma cells, cerebral organoids, and several different cell populations from the brain: fetal neurons (replicating and quiescence), microglia, and astrocytes (Supplementary Figure 32 and Supplementary Table 58). Schizophrenia was not significantly associated (FDR < 0.05) with any gene module tested in our analysis. None of these LVs were significantly aligned to prior pathways, which might represent potentially novel transcriptional processes affecting the cardiovascular and central nervous systems.

## Discussion

---

We have introduced a novel computational strategy that integrates statistical associations from TWAS with groups of genes (gene modules) that have similar expression patterns across the same cell types. Our key innovation is that we project gene-trait associations through a latent representation derived not strictly from measures of normal tissue but also cell types under a variety of stimuli and at various developmental stages. This improves interpretation by going beyond statistical associations to infer cell type-specific features of complex phenotypes. We found that our approach can identify disease-relevant cell types from summary statistics, and several disease-associated gene modules were replicated in eMERGE. Using a CRISPR screen to analyze lipid regulation, we found that our gene module-based approach can prioritize causal genes even when single gene associations are not detected. We interpret these findings with an omnigenic perspective of “core” and “peripheral” genes, suggesting that the approach can identify genes that directly affect the trait with no mediated regulation of other genes, and thus prioritize alternative and potentially more attractive therapeutic targets. Using our gene module perspective, we also integrated drug-induced transcriptional profiles, which allowed us to connect diseases, drugs, and cell types. Furthermore, and beyond statistical prediction, we focused on a particular drug (niacin) and set of traits (cardiovascular diseases) to show that the approach connects disease-relevant transcriptional processes with known mechanisms of action. This suggests that the conceptual approach may reveal the mechanisms of pharmacological effect of known or experimental drugs. Finally, we found that the analysis of associations through latent representations provided reasonable groupings of diseases and traits affected by shared and distinct transcriptional mechanisms expressed in highly relevant tissues.

In some cases, the features/LVs linked to phenotypes appear to be associated with specific cell types. Associations with such cell type marker genes may reveal potentially causal cell types for a phenotype with more precision. We observed modules expressed primarily in one tissue (such as adipose in LV246, thyroid in LV155, or ovary in LV66). Others appeared to be expressed in many contexts, and these may capture pathways associated with a set of related complex diseases. For example, LV136 is associated with cardiovascular disease and measures of corneal biomechanics, and expressed in fibroblasts, osteoblasts, pancreas, liver, and cardiomyocytes, among others. Another example is LV844, expressed in whole blood samples and strongly associated with a range of autoimmune diseases. From an omnigenic point of view, these patterns might represent cases of “network pleiotropy,” where the same cell types mediate molecularly related traits. To our knowledge, projection through a representation learned on complementary but distinct datasets is a novel approach to identify cell type and pathway effects on complex phenotypes that is computationally simple to implement.

Our approach rests on the assumption that gene modules with coordinated expression patterns will also manifest coordinated pathological effects. Our implementation in this work integrates two complementary approaches. The first is MultiPLIER, which extracts latent variables from large expression datasets, and these LVs could represent either real transcriptional processes or technical factors (“batch effects”). We used a previously published model derived from recount2, which was designed to analyze rare disorders but might not be the optimal latent representation for the wide range of complex diseases considered here. Also, the underlying factorization method rests on linear combinations of variables, which could miss important and more complex co-expression patterns. In addition, recount2, the training dataset used, has since been surpassed in size and scale by other resources [15,84]. The second approach we used in this study is TWAS, where we are only considering the hypothesis that GWAS loci affect traits via changes in gene expression, and other effects such as coding variants disrupting protein-protein interactions are not captured. Additionally, TWAS has several limitations that can lead to false positives [85,86]. Like GWAS, which generally detects groups of associated variants in linkage disequilibrium (LD), TWAS usually identifies several genes within the same locus [20,87]. This is due to sharing of GWAS variants in gene expression models, correlated expression of nearby genes, or even correlation of their predicted expression due to eQTLs in LD, among others [85]. Larger datasets and methods designed to learn representations with this application in mind could further refine the approach and are a promising avenue for future research.

Our findings are concordant with previous studies showing that drugs with genetic support are more likely to succeed through the drug development pipeline [7,49]. In this case, projecting association results through latent variables better prioritized disease-treatment pairs than considering single-gene effects alone. An additional benefit is that the latent variables driving predictions can be examined to infer potential mechanisms of action. Here we prioritized drugs for diseases with very different tissue etiologies, and a challenge of the approach is to select the most appropriate tissue model from TWAS to find reversed transcriptome patterns between genes and drug-induced perturbations. We also demonstrated that clustering trees, introduced initially as a means to examine developmental processes in single-cell data, provide a multi-resolution grouping of phenotypes based on latent variable associations. We employed hard-partitioning algorithms (one trait belongs exclusively to one cluster) where the distance between two traits takes into account all gene modules. However, it is also plausible for two complex diseases to share only a few biological processes instead of being similar across most of them. In this portion, we used S-MultiXcan associations, which only provide the association strength between a gene and a trait, but with no direction of effect. This does mean that traits are grouped based on associated genes, but genes could have opposite effects on traits within the same cluster. Considering groups of related diseases was previously shown to be more powerful to detect shared genetic etiology [88,89], and clustering trees provide a way to explore such relationships in the context of latent variables. Finally, our TWAS results were derived from a large set of GWAS of different sample sizes and qualities. Although the potential issues derived from this data heterogeneity were addressed before performing cluster analysis of traits, data preprocessing steps are always challenging and might not avoid bias altogether.

Ultimately, the quality of the representations is essential to performance. Here we used a representation derived from a factorization of bulk RNA-seq data. Detailed perturbation datasets and single-cell profiling of tissues, with and without perturbagens, and at various stages of development provide an avenue to generate higher quality and more interpretable representations. On the other hand, the key to interpretability is driven by the annotation of sample metadata. New approaches to infer and annotate with structured metadata are promising and can be directly applied to existing data [90]. Rapid improvements in both areas set the stage for latent variable projections to be widely applied to disentangle the genetic basis of complex human phenotypes. By providing a new perspective for a mechanistic understanding of statistical associations from TWAS, our method can generate testable hypotheses for the post-GWAS functional characterization of complex diseases, which will likely be an area of great importance in the coming years.

## Methods and materials

---

PhenoPLIER is a framework that combines different computational approaches to integrate gene-trait associations and drug-induced transcriptional responses with groups of functionally-related genes (referred to as gene modules or latent variables/LVs). Gene-trait associations are computed using the PrediXcan family of methods, whereas latent variables are inferred by the MultiPLIER models applied on large gene expression compendia. PhenoPLIER provides 1) a regression model to compute an LV-trait association, 2) a consensus clustering approach applied to the latent space to learn shared and distinct transcriptomic properties between traits, and 3) an interpretable, LV-based drug repurposing framework. We provide the details of these methods below.

### The PrediXcan family of methods for gene-based associations

We used Summary-PrediXcan (S-PrediXcan) [91] and Summary-MultiXcan (S-MultiXcan) [19] as the gene-based statistical approaches, which belong to the PrediXcan family of methods [20]. We broadly refer to these approaches as TWAS (transcription-wide association studies). S-PrediXcan, the summary-based version of PrediXcan, computes the univariate association between a trait and a gene's predicted expression in a single tissue. In contrast, S-MultiXcan, the summary-based version of

MultiXcan, computes the joint association between a gene's predicted expression in all tissues and a trait. S-PrediXcan and S-MultiXcan only need GWAS summary statistics instead of individual-level genotype and phenotype data.

Here we briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to  $\mathbf{y}$  as a vector of traits for  $n$  individuals that is centered for convenience (so that no intercept is necessary);  $\tilde{\mathbf{t}}_l = \sum_{a \in \text{model}_l} w_a^l X_a$  is the gene's predicted expression for all individuals in tissue  $l$ ,  $X_a$  is the genotype of SNP  $a$  and  $w_a$  its weight in the tissue prediction model  $l$ ; and  $\mathbf{t}_l$  is the standardized version of  $\tilde{\mathbf{t}}_l$  with mean equal to zero and standard deviation equal to one.

S-PrediXcan [91] is the summary version of PrediXcan [20]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$\mathbf{y} = \mathbf{t}_l \gamma_l + \boldsymbol{\epsilon}_l, \quad (1)$$

where  $\hat{\gamma}_l$  is the estimated effect size or regression coefficient, and  $\boldsymbol{\epsilon}_l$  are the error terms with variance  $\sigma_\epsilon^2$ . The significance of the association is assessed by computing the  $z$ -score  $\hat{z}_l = \hat{\gamma}_l / \text{se}(\hat{\gamma}_l)$  for a gene's tissue model  $l$ . PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan  $z$ -scores using only GWAS summary statistics with the expression

$$\hat{z}_l \approx \sum_{a \in \text{model}_l} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\text{se}(\hat{\beta}_a)}, \quad (2)$$

where  $\hat{\sigma}_a$  is the variance of SNP  $a$ ,  $\hat{\sigma}_l$  is the variance of the predicted expression of a gene in tissue  $l$ , and  $\hat{\beta}_a$  is the estimated effect size of SNP  $a$  from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [4] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the  $z$ -scores in our drug repurposing approach (described below).

S-MultiXcan [19], on the other hand, is the summary version of MultiXcan. MultiXcan is more powerful than PrediXcan in detecting gene-trait associations, although it does not provide the direction of effects. Its main output is the  $p$ -value (obtained with an F-test) of the multiple tissue model

$$\begin{aligned} \mathbf{y} &= \sum_{l=1}^p \mathbf{t}_l g_l + \mathbf{e} \\ &= \mathbf{Tg} + \mathbf{e}, \end{aligned} \quad (3)$$

where  $\mathbf{T}$  is a matrix with  $p$  columns  $\mathbf{t}_l$ ,  $\hat{g}_l$  is the estimated effect size for the predicted gene expression in tissue  $l$  (and thus  $\hat{\mathbf{g}}$  is a vector with  $p$  estimated effect sizes  $\hat{g}_l$ ), and  $\mathbf{e}$  are the error terms with variance  $\sigma_e^2$ . Given the high correlation between predicted expression values for a gene across different tissues, MultiXcan uses the principal components (PCs) of  $\mathbf{T}$  to avoid collinearity issues. S-MultiXcan derives the joint regression estimates (effect sizes and their variances) in Equation (3) using the marginal estimates from S-PrediXcan in Equation (2). Under the null hypothesis of no

association,  $\hat{\mathbf{g}}^\top \frac{\mathbf{T}^\top \mathbf{T}}{\sigma_e^2} \hat{\mathbf{g}} \sim \chi_p^2$ , and therefore the significance of the association in S-MultiXcan is estimated with

$$\begin{aligned} \frac{\hat{\mathbf{g}}^\top (\mathbf{T}^\top \mathbf{T}) \hat{\mathbf{g}}}{\sigma_e^2} &\approx \hat{\gamma}^\top \frac{\sqrt{n-1}}{\sigma_\epsilon} \left( \frac{\mathbf{T}^\top \mathbf{T}}{n-1} \right)^{-1} \frac{\sqrt{n-1}}{\sigma_\epsilon} \hat{\gamma} \\ &= \hat{\mathbf{z}}^\top \text{Cor}(\mathbf{T})^{-1} \hat{\mathbf{z}}, \end{aligned} \quad (4)$$

where  $\hat{\mathbf{z}}$  is a vector with  $p$   $z$ -scores (Equation (2)) for each tissue available for the gene, and  $\text{Cor}(\mathbf{T})$  is the autocorrelation matrix of  $\mathbf{T}$ . Since  $\mathbf{T}^\top \mathbf{T}$  is singular for many genes, S-MultiXcan computes the pseudo-inverse  $\text{Cor}(\mathbf{T})^+$  using the  $k$  top PCs, and thus  $\hat{\mathbf{z}}^\top \text{Cor}(\mathbf{T})^+ \hat{\mathbf{z}} \sim \chi_k^2$ . To arrive at this expression, S-MultiXcan uses the conservative approximation  $\sigma_e^2 \approx \sigma_\epsilon^2$ , that is, the variance of the error terms in the joint regression is approximately equal to the residual variance of the marginal regressions. Another important point is that  $\text{Cor}(\mathbf{T})$  is estimated using a global genotype covariance matrix, whereas marginal  $\hat{z}_l$  in Equation (2) are approximated using tissue-specific genotype covariances. Although S-MultiXcan yields highly concordant estimates compared with MultiXcan, results are not perfectly correlated across genes [19]. As we explain later, these differences are important for our LV-based regression model when computing the gene-gene correlation matrix. We used S-MultiXcan results for our LV-based regression model and our cluster analyses of traits.

## TWAS resources

We used two large TWAS resources from different cohorts for discovery and replication. PhenomeXcan [32], our discovery cohort, provides results on 4,091 traits across different categories. Supplemenetary File XXX has all the details about the included GWAS, sample size and disease/trait categories. (add phenotyp\_info file with categories like in emerge). In PhenomeXcan, these publicly available GWAS summary statistics were used to compute 1) gene-based associations with the PrediXcan family of methods (described before), and 2) a posterior probability of colocalization between GWAS loci and *cis*-eQTL with fastENLOC [32,86]. We refer to the matrix of  $z$ -scores from S-PrediXcan (Equation (2)) across  $q$  traits and  $m$  genes in tissue  $t$  as  $\mathbf{M}^t \in \mathbb{R}^{q \times m}$ . As explained later, matrices  $\mathbf{M}^t$  were used in our LV-based drug repurposing framework since they provide direction of effects. The S-MultiXcan results (22,515 gene associations across 4,091 traits) were used in our LV-based regression framework and our cluster analyses of traits. For the cluster analyses, we used the  $p$ -values converted to  $z$ -scores:  $\mathbf{M} = \Phi^{-1}(1 - p/2)$ , where  $\Phi^{-1}$  is the probit function. Higher  $z$ -scores correspond to stronger associations.

Our discovery cohort was eMERGE [36], where the same TWAS methods were run on 309 phecodes [37] across different categories (more information about traits are available in [37]). We used these results to replicate the associations found with our LV-based regression framework in PhenomeXcan.

## MultiPLIER and Pathway-level information extractor (PLIER)

MultiPLIER [34] extracts patterns of co-expressed genes from recount2 [14], a large gene expression dataset. The approach applies the pathway-level information extractor method (PLIER) [35], which performs unsupervised learning using prior knowledge (canonical pathways) to reduce technical noise. PLIER uses a matrix factorization approach that deconvolutes gene expression data into a set of latent variables (LV), where each LV represents a gene module. The MultiPLIER models reduced the dimensionality in recount2 to 987 LVs.

Given a gene expression dataset  $\mathbf{Y}^{m \times c}$  with  $m$  genes and  $c$  experimental conditions and a prior knowledge matrix  $\mathbf{C} \in \{0, 1\}^{m \times p}$  for  $p$  MSigDB pathways [92] (so that  $\mathbf{C}_{ij} = 1$  if gene  $i$  belongs to pathway  $j$ ), PLIER finds  $\mathbf{U}$ ,  $\mathbf{Z}$ , and  $\mathbf{B}$  minimizing

$$\|\mathbf{Y} - \mathbf{Z}\mathbf{B}\|_F^2 + \lambda_1 \|\mathbf{Z} - \mathbf{C}\mathbf{U}\|_F^2 + \lambda_2 \|\mathbf{B}\|_F^2 + \lambda_3 \|\mathbf{U}\|_{L^1} \quad (5)$$

subject to  $\mathbf{U} > 0$ ,  $\mathbf{Z} > 0$ ;  $\mathbf{Z}^{m \times l}$  are the gene loadings with  $l$  latent variables,  $\mathbf{B}^{l \times c}$  is the latent space for  $c$  conditions,  $\mathbf{U}^{p \times l}$  specifies which of the  $p$  prior-information pathways in  $\mathbf{C}$  are represented for each LV, and  $\lambda_i$  are different regularization parameters used in the training step.  $\mathbf{Z}$  is a low-dimensional representation of the gene space where each LV aligns as much as possible to prior knowledge, and it might represent either a known or novel gene module (i.e., a meaningful biological pattern) or noise.

For our drug repurposing and cluster analyses, we used this model to project gene-trait (from TWAS) and gene-drug associations (from LINCS L1000) into this low-dimensional gene module space. For instance, TWAS associations  $\mathbf{M}$  (either from S-PrediXcan or S-MultiXcan) were projected using

$$\hat{\mathbf{M}} = (\mathbf{Z}^\top \mathbf{Z} + \lambda_2 \mathbf{I})^{-1} \mathbf{Z}^\top \mathbf{M}, \quad (6)$$

where  $\hat{\mathbf{M}}^{l \times q}$  is a matrix where traits are represented by gene modules instead of single genes. As explained later, we used the same approach to project drug-induced transcriptional profiles in LINCS L1000 to obtain a representation of drugs using gene modules.

## Regression model for LV-trait associations

We adapted the gene-set analysis framework from MAGMA [41] to TWAS. We used a competitive test to predict gene-trait associations from TWAS using gene weights from an LV, testing whether top-weighted genes for an LV are more strongly associated with the phenotype than other genes with relatively small or zero weights. Thus, we fit the model

$$\mathbf{m} = \beta_0 + \mathbf{s}\beta_s + \sum_i \mathbf{x}_i \beta_i + \epsilon, \quad (7)$$

where  $\mathbf{m}$  is a vector of S-MultiXcan gene  $p$ -values for a trait (with a  $-\log_{10}$  transformation);  $\mathbf{s}$  is a binary indicator vector with  $s_\ell = 1$  for the top 1% of genes with the largest loadings for LV  $\ell$  (from  $\mathbf{Z}_\ell$ ) and zero otherwise;  $\mathbf{x}_i$  is a gene property used as a covariate;  $\beta$  are effect sizes (with  $\beta_0$  as the intercept); and  $\epsilon \sim \text{MVN}(0, \sigma^2 \mathbf{R})$  is a vector of error terms with a multivariate normal distribution (MVN) where  $\mathbf{R}$  is the matrix of gene correlations.

The model tests the null hypothesis  $\beta_s = 0$  against the one-sided hypothesis  $\beta_s > 0$ . Therefore,  $\beta_s$  reflects the difference in trait associations between genes that are part of LV  $\ell$  and genes outside of it. Following the MAGMA framework, we used two gene properties as covariates: 1) *gene size*, defined as the number of PCs retained in S-MultiXcan, and 2) *gene density*, defined as the ratio of the number of PCs to the number of tissues available.

Since the error terms  $\epsilon$  could be correlated, we cannot assume they have independent normal distributions as in a standard linear regression model. In the PrediXcan family of methods, the

predicted expression of a pair of genes could be correlated if they share eQTLs or if these are in LD [85]. Therefore, we used a generalized least squares approach to account for these correlations. The gene-gene correlation matrix  $\mathbf{R}$  was approximated by computing the correlations between the model sum of squares (SSM) for each pair of genes under the null hypothesis of no association. These correlations are derived from the individual-level MultiXcan model (Equation (3)), where the predicted expression matrix  $\mathbf{T}_i \in \mathbb{R}^{n \times p_i}$  of a gene  $i$  across  $p_i$  tissues is projected into its top  $k_i$  PCs, resulting in matrix  $\mathbf{P}_i \in \mathbb{R}^{n \times k_i}$ . From the MAGMA framework, we know that the SSM for each gene is proportional to  $\mathbf{y}^\top \mathbf{P}_i \mathbf{P}_i^\top \mathbf{y}$ . Under the null hypothesis of no association, the covariances between the SSMs of genes  $i$  and  $j$  is therefore given by  $2 \times \text{Trace}(\mathbf{P}_i^\top \mathbf{P}_j \mathbf{P}_j^\top \mathbf{P}_i)$ . The standard deviations of each SSM are given by  $\sqrt{2 \times k_i} \times (n - 1)$ . Therefore, the correlation between the SSMs for genes  $i$  and  $j$  can be written as follows:

$$\begin{aligned}\mathbf{R}_{ij} &= \frac{2 \times \text{Tr}(\mathbf{P}_i^\top \mathbf{P}_j \mathbf{P}_j^\top \mathbf{P}_i)}{\sqrt{2 \times k_i} \times \sqrt{2 \times k_j} \times (n - 1)^2} \\ &= \frac{2 \times \text{Tr}(\text{Cor}(\mathbf{P}_i, \mathbf{P}_j) \times \text{Cor}(\mathbf{P}_j, \mathbf{P}_i))}{\sqrt{2 \times k_i} \times \sqrt{2 \times k_j}},\end{aligned}\tag{8}$$

where columns  $\mathbf{P}$  are standardized,  $\text{Tr}$  is the trace of a matrix, and the cross-correlation matrix between PCs  $\text{Cor}(\mathbf{P}_i, \mathbf{P}_j) \in \mathbb{R}^{k_i \times k_j}$  is given by

$$\begin{aligned}\text{Cor}(\mathbf{P}_i, \mathbf{P}_j) &= \text{Cor}(\mathbf{T}_i \mathbf{V}_i^\top \text{diag}(\lambda_i)^{-1/2}, \mathbf{T}_j \mathbf{V}_j^\top \text{diag}(\lambda_j)^{-1/2}) \\ &= \text{diag}(\lambda_i)^{-1/2} \mathbf{V}_i \left( \frac{\mathbf{T}_i^\top \mathbf{T}_j}{n - 1} \right) \mathbf{V}_j^\top \text{diag}(\lambda_j)^{-1/2},\end{aligned}\tag{9}$$

where  $\frac{\mathbf{T}_i^\top \mathbf{T}_j}{n - 1} \in \mathbb{R}^{p_i \times p_j}$  is the cross-correlation matrix between the predicted expression levels of genes  $i$  and  $j$ , and columns of  $\mathbf{V}_i$  and scalars  $\lambda_i$  are the eigenvectors and eigenvalues of  $\mathbf{T}_i$ , respectively. S-MultiXcan keeps only the top eigenvectors using a condition number threshold of  $\frac{\max(\lambda_i)}{\lambda_i} < 30$ . To estimate the correlation of predicted expression levels for genes  $i$  in tissue  $k$  and gene  $j$  in tissue  $l$ ,  $(\mathbf{t}_k^i, \mathbf{t}_l^j)$  ( $\mathbf{t}_k^i$  is the  $k$ th column of  $\mathbf{T}_i$ ), we used [19]

$$\begin{aligned}
\frac{(\mathbf{T}_i^\top \mathbf{T}_j)_{kl}}{n-1} &= Cor(\mathbf{t}_k^i, \mathbf{t}_l^j) \\
&= \frac{Cov(\mathbf{t}_k, \mathbf{t}_l)}{\sqrt{\widehat{\text{var}}(\mathbf{t}_k)\widehat{\text{var}}(\mathbf{t}_l)}} \\
&= \frac{Cov(\sum_{a \in \text{model}_k} w_a^k X_a, \sum_{b \in \text{model}_l} w_b^l X_b)}{\sqrt{\widehat{\text{var}}(\mathbf{t}_k)\widehat{\text{var}}(\mathbf{t}_l)}} \\
&= \frac{\sum_{\substack{a \in \text{model}_k \\ b \in \text{model}_l}} w_a^k w_b^l Cov(X_a, X_b)}{\sqrt{\widehat{\text{var}}(\mathbf{t}_k)\widehat{\text{var}}(\mathbf{t}_l)}} \\
&= \frac{\sum_{\substack{a \in \text{model}_k \\ b \in \text{model}_l}} w_a^k w_b^l \Gamma_{ab}}{\sqrt{\widehat{\text{var}}(\mathbf{t}_k)\widehat{\text{var}}(\mathbf{t}_l)}}, 
\end{aligned} \tag{10}$$

where  $X_a$  is the genotype of SNP  $a$ ,  $w_a^k$  is the weight of SNP  $a$  for gene expression prediction in the tissue model  $k$ , and  $\Gamma = \widehat{\text{var}}(\mathbf{X}) = (\mathbf{X} - \bar{\mathbf{X}})^\top (\mathbf{X} - \bar{\mathbf{X}})/(n-1)$  is the genotype covariance matrix using GTEx v8 as the reference panel, which is the same used in all TWAS methods described here. The variance of the predicted expression values of gene  $i$  in tissue  $k$  is estimated as [91]:

$$\begin{aligned}
\widehat{\text{var}}(\mathbf{t}_k^i) &= (\mathbf{W}^k)^\top \Gamma^k \mathbf{W}^k \\
&= \sum_{\substack{a \in \text{model}_k \\ b \in \text{model}_k}} w_a^k w_b^k \Gamma_{ab}^k. 
\end{aligned} \tag{11}$$

Note that, since we used the MultiXcan regression model (Equation (3)),  $\mathbf{R}$  is only an approximation of gene correlations in S-MultiXcan. As explained before, S-MultiXcan approximates the joint regression parameters in MultiXcan using the marginal regression estimates from S-PrediXcan in (2) with some simplifying assumptions and different genotype covariance matrices. This complicates the derivation of an S-MultiXcan-specific solution to compute  $\mathbf{R}$ . To account for this, we used a submatrix  $\mathbf{R}_\ell$  corresponding to genes that are part of LV  $\ell$  only (top 1% of genes) instead of the entire matrix  $\mathbf{R}$ . This simplification is conservative since correlations are accounted for top genes only. Our simulations (Supplementary Note XXX) show that the model is approximately well-calibrated and can correct for LVs with adjacent and highly correlated genes at the top (Supplementary Figure YYY). The model can also detect LVs associated with relevant traits (Figure 2 and Table 8) that are replicated in a different cohort (Table 9).

In Equation (10), we only considered SNPs present in GWAS used as input for the TWAS approaches, since otherwise correlations would not be accurately estimated [19]. Therefore, we computed different correlation matrices for PhenomeXcan and eMERGE. In PhenomeXcan, most of the GWAS (4,049) were obtained from the UK Biobank using the same pipeline and including the same set of SNPs, so a single correlation matrix was used for this set. For the rest, we used a single correlation matrix for each group of traits that shared the same or most of the SNPs.

We ran our regression model for all 987 LVs across the 4,091 traits in PhenomeXcan. For replication, we ran the model in the 309 phecodes in eMERGE. We adjusted the  $p$ -values using the Benjamini-Hochberg procedure.

## LV-based drug repurposing approach

For the drug-disease prediction, we derived an LV-based method based on a drug repositioning framework previously used for psychiatry traits [49], where individual/single genes associated with a trait are anticorrelated with expression profiles for drugs. We compared our LV-based method with this previously published, single-gene approach. For the single-gene method, we computed a drug-disease score by multiplying each S-PrediXcan set of results in tissue  $t$ ,  $\mathbf{M}^t$ , with the transcriptional responses profiled in LINCS L1000 [33],  $\mathbf{L}^{c \times m}$  (for  $c$  compounds):  $\mathbf{D}^{t,k} = -1 \cdot \mathbf{M}^{t,k} \mathbf{L}^\top$ , where  $k$  refers to the number of most significant gene associations in  $\mathbf{M}^t$  for each trait. As suggested in [49],  $k$  could be either all genes or the top 50, 100, 250, and 500; then, we averaged score ranks across all  $k$  and obtained  $\mathbf{D}^t$ . Finally, for each drug-disease pair, we took the maximum prediction score across all tissues:  $\mathbf{D}_{ij} = \max\{\mathbf{D}_{ij}^t \mid \forall t\}$ .

The same procedure was used for the LV-based approach, where we projected  $\mathbf{M}^t$  and  $\mathbf{L}$  into the gene module latent space using Equation (6), leading to  $\hat{\mathbf{M}}^t$  and  $\hat{\mathbf{L}}^{l \times c}$ , respectively. Finally,  $\mathbf{D}^{t,k} = -1 \cdot \hat{\mathbf{L}}^\top \hat{\mathbf{M}}^{t,k}$ , where in this case  $k$  could be all LVs or the top 5, 10, 25 and 50 (since we have an order of magnitude less LVs than genes).

Since the gold standard of drug-disease medical indications is described with Disease Ontology IDs (DOID) [93], we mapped PhenomeXcan traits to the Experimental Factor Ontology [94] using [95], and then to DOID.

## Consensus clustering of traits

We performed two preprocessing steps on the S-MultiXcan results before the cluster analysis. First, we combined results in  $\mathbf{M}$  (with  $p$ -values converted to  $z$ -scores, as described before) for traits that mapped to the same Experimental Factor Ontology (EFO) [94] term using the Stouffer's method:

$\sum w_i M_{ij} / \sqrt{\sum w_i^2}$ , where  $w_i$  is a weight based on the GWAS sample size for trait  $i$ , and  $M_{ij}$  is the  $z$ -score for gene  $j$ . Second, we divided all  $z$ -scores for each trait  $i$  by their sum to reduce the effect of highly polygenic traits:  $M_{ij} / \sum M_{ij}$ . Finally, we projected this data matrix using Equation (6), obtaining  $\hat{\mathbf{M}}$  with  $n=3,752$  traits and  $l=987$  LVs as the input of our clustering pipeline.

A partitioning of  $\hat{\mathbf{M}}$  with  $n$  traits into  $k$  clusters is represented as a label vector  $\pi \in \mathbb{N}^n$ . Consensus clustering approaches consist of two steps: 1) the generation of an ensemble  $\Pi$  with  $r$  partitions of the dataset:  $\Pi = \{\pi_1, \pi_2, \dots, \pi_r\}$ , and 2) the combination of the ensemble into a consolidated solution defined as:

$$\pi^* = \arg \max_{\hat{\pi}} Q(\{|\mathcal{L}^i| \phi(\hat{\pi}_{\mathcal{L}^i}, \pi_{i\mathcal{L}^i}) \mid i \in \{1, \dots, r\}\}), \quad (12)$$

where  $\mathcal{L}^i$  is a set of data indices with known cluster labels for partition  $i$ ,  $\phi: \mathbb{N}^n \times \mathbb{N}^n \rightarrow \mathbb{R}$  is a function that measures the similarity between two partitions, and  $Q$  is a measure of central tendency, such as the mean or median. We used the adjusted Rand index (ARI) [96] for  $\phi$  and the median for  $Q$ . To obtain  $\pi^*$ , we define a consensus function  $\Gamma: \mathbb{N}^{n \times r} \rightarrow \mathbb{N}^n$  with  $\Pi$  as the input. We used consensus functions based on the evidence accumulation clustering (EAC) paradigm [97], where  $\Pi$  is first transformed into a distance matrix  $\mathbf{D}_{ij} = d_{ij}/r$ , where  $d_{ij}$  is the number of times traits  $i$  and  $j$  were grouped in different clusters across all  $r$  partitions in  $\Pi$ . Then,  $\Gamma$  can be any similarity-based clustering algorithm, which is applied on  $\mathbf{D}$  to derive the final partition  $\pi^*$ .

For the ensemble generation step, we used different algorithms to create a highly diverse set of partitions (see Figure 5) since diversity is an important property for ensembles [98,99,100]. We used three data representations: the raw dataset, its projection into the top 50 principal components, and the embedding learned by UMAP [101] using 50 components. For each of these, we applied five clustering algorithms covering a wide range of different assumptions on the data structure:  $k$ -means [102], spectral clustering [103], a Gaussian mixture model (GMM), hierarchical clustering, and DBSCAN [104]. For  $k$ -means, spectral clustering and GMM, we specified a range of  $k$  between 2 and  $\sqrt{n} \approx 60$ , and for each  $k$  we generated five partitions using random seeds. For hierarchical clustering, for each  $k$ , we generated four partitions using common linkage criteria: ward, complete, average and single. For DBSCAN, we combined different ranges for parameters  $\epsilon$  (the maximum distance between two data points to be considered part of the same neighborhood) and  $minPts$  (the minimum number of data points in a neighborhood for a data point to be considered a core point), based on the procedure in [105]. Specifically, we used  $minPts$  values from 2 to 125. For each data representation (raw, PCA and UMAP), we determined a plausible range of  $\epsilon$  values by observing the distribution of the mean distance of the  $minPts$ -nearest neighbors across all data points. Since some combinations of  $minPts$  and  $\epsilon$  might not produce a meaningful partition (for instance, when all points are detected as noisy or only one cluster is found), we resampled partitions generated by DBSCAN to ensure an equal representation of this algorithm in the ensemble. This procedure generated a final ensemble of 4,428 partitions of 3,752 traits.

Finally, we used spectral clustering on  $\mathbf{D}$  to derive the final consensus partitions.  $\mathbf{D}$  was first transformed into a similarity matrix by applying an RBF kernel  $\exp(-\gamma\mathbf{D}^2)$  using four different values for  $\gamma$  that we empirically determined to work best. Therefore, for each  $k$  between 2 and 60, we derived four consensus partitions and selected the one that maximized Equation (12). We further filtered this set of 59 solutions to keep only those with an ensemble agreement larger than the 75th percentile, leaving a total of 15 final consensus partitions shown in Figure 6.

The input data in our clustering pipeline undergoes several linear and nonlinear transformations, including PCA, UMAP and the ensemble transformation using the EAC paradigm (distance matrix  $\mathbf{D}$ ). Although consensus clustering has clear advantages for biological data [106], this set of data transformations complicates the interpretation of results. To circumvent this, we used a supervised learning approach to detect which gene modules/LVs are the most important for each cluster of traits (Figure 5 b). **To address reviewer comment:** Note that we did not use this supervised model for prediction but only to learn which features (LVs) were most discriminative for each cluster. For this, we used the highest resolution partition ( $k=29$ , although any could be used) to train a decision tree model using each of the clusters as labels and the projected data  $\hat{\mathbf{M}}$  as the training samples. For each  $k$ , we built a set of binary labels with the current cluster's traits as the positive class and the rest of the traits as the negative class. Then, we selected the LV in the root node of the trained model only if its threshold was positive and larger than one standard deviation. Next, we removed this LV from  $\hat{\mathbf{M}}$  (regardless of being previously selected or not) and trained the model again. We repeated this procedure 20 times to extract the top 20 LVs that better discriminate traits in a cluster from the rest.

## CRISPR-Cas9 screening

**Cell culture.** HepG2 cells were obtained from ATCC (ATCC® HB-8065™), and maintained in Eagle's Minimum Essential Medium with L-Glutamine (EMEM, Cat. 112-018-101, Quality Biology) supplemented with 10% Fetal Bovine Serum (FBS, Gibco, Cat.16000-044), and 1% Pen/Strep (Gibco, Cat.15140-122). Cells were kept at 37°C in a humidity-controlled incubator with 5% CO<sub>2</sub>, and were maintained at a density not exceeding more than 80% confluence.

**Genome-wide lentiviral pooled CRISPR-Cas9 library.** 3rd lentiviral generation, Broad GPP genome-wide Human Brunello CRISPR knockout Pooled library was provided by David Root and John Doench

from Addgene (Cat. 73179-LV), and was used for HepG2 cell transduction. It consists of 76,441 sgRNAs, and targets 19,114 genes in the human genome with an average of 4 sgRNAs per gene. Each 20nt sgRNA cassette was inserted into the lentiCRISPR-PRv2 backbone between U6 promoter and gRNA scaffold. Through cell transduction, the lentiviral vectors which encode Cas9 were used to deliver the sgRNA cassette containing plasmids into cells during cell replication. Unsuccessful transduced cells were excluded through puromycin selection.

**Lentiviral titer determination.** No-spin lentiviral transduction was utilized for the screen. In a Collagen-I coated 6-wells plate, approximate 2.5 M cells were seeded each well in the presence of 8ug/ml polybrene (Millipore Sigma, Cat. TR-1003 G), and a different titrated virus volume (e.g., 0, 50, 100, 200, 250, and 400ul) was assigned to each well. EMEM complete media was added to make the final volume of 1.24ml. 16-18hrs post-transduction, virus/polybrene-containing media was removed from each well. Cells were washed twice with 1x DPBS and replaced with fresh EMEM. At 24h, cells in each well were trypsinized, diluted (e.g., 1:10), and seeded in pairs of wells of 6-well plates. At 60hr post-transduction, cell media in each well was replaced with fresh EMEM. 2ug/ml of puromycin (Gibco, Cat. A1113803) was added to one well out of the pair. 2-5 days after puromycin selection, or the 0 virus well treated with puromycin had no survival of cells, cells in both wells with/without puromycin were collected and counted for viability. Percentage of Infection (PI%) was obtained by comparing the cell numbers with/without puromycin selection within each pair. By means of Poisson's distribution theory, when transduction efficiency (PI%) is between 30-50%, which corresponds to an MOI (Multiplicity of Infection) of ~0.35-0.70. At MOI equal to or close to 0.3, around 95% of infected cells are predicted to have only one copy of the virus. Therefore, a volume of virus (120ul) yielding 30-40% of transduction efficiency was chosen for further large-scale viral transduction.

**Lentiviral Transduction in HepG2 Using Brunello CRISPR Knockout Pooled Library.** In order to achieve a coverage (representation) of at least 500 cells per sgRNA, and at an MOI between 0.3-0.4 to ensure 95% of infected cells get only one viral particle per cell, ~200M cells were initiated for the screen. Transduction was carried out in a similar fashion as described above. Briefly, 2.5M cells were seeded in each well of 14 6-well plates, along with 8ug/ml of polybrene. A volume of 120ul of the virus was added to each experimental well. 18hrs post-transduction, virus/PB mix medium was removed, and cells in each well were collected, counted, and pooled into T175 flasks. At 60hr post-transduction, 2ug/ml of puromycin was added to each flask. Mediums were changed every two days with fresh EMEM, topped with 2ug/ml puromycin. Seven days after puromycin selection, cells were collected, pooled, counted, and replated.

**Fluorescent dye staining.** 9 days after puromycin selection, cells were assigned to 2 groups. 20-30M cells were collected as Unsorted Control. The cell pellet was spun down at 500 x g for 5min at 4oC. The dry pellet was kept at -80oC for further genomic DNA isolation. The rest of the cells (approximately 200M) were kept in 100mm dishes and stained with a fluorescent dye (LipidSpotTM 488, Biotium, Cat. 70065-T). In Brief, LipidSpot 488 was diluted to 1:100 with DPBS. 4ml of staining solution was used for each dish and incubated at 37oC for 30min. Cell images were captured through fluorescent microscope EVOS for GFP signal detection (Supplementary Figure 8).

**Fluorescence-activated cell sorting (FACS).** Cells were immediately collected into 50ml tubes (From this point on, keep cells cold), and spun at 500 x g for 5min at 4oC. After DPBS wash, cell pellets were resuspended with FACS Sorting Buffer (1x DPBS without Ca<sup>2+</sup>/Mg<sup>2+</sup>, 2.5mM EDTA, 25mM HEPES, 1% BSA. The solution was filter sterilized, and kept at 4oC), pi-pet gently to make single cells. The cell solution was then filtered through a cell strainer (Falcon, Cat. 352235) and was kept on ice, protected from light. Collected cells were sorted on FACSJazz. 100um nozzle was used for sorting. ~20% of each GFP-High and GFP-Low (Supplementary Figure 9) were collected into 15ml tubes. After sorting, cells were immediately spun down. Pellets were kept at -80oC for further genomic DNA isolation.

**Genomic DNA isolation and verification.** Three conditions of Genomic DNA (Un-Sorted Control, lentiV2 GFP-High, and lentiV2 GFP-Low) were extracted using QIAamp DNA Blood Mini Kit (Qiagen, Cat.51104), followed by UV Spectroscopy (Nanodrop) to access the quality and quantity of the gDNA. A total of 80-160ug of gDNA was isolated for each condition. sgRNA cassette and lentiviral specific transgene in isolated gDNA were verified through PCR (Supplementary Figure [10](#)).

**Illumina libraries generation and sequencing.** The fragment containing sgRNA cassette was amplified using P5 /P7 primers, as indicated in [\[107\]](#), and primer sequences were adapted from Broad Institute protocol (Supplementary Figure [11](#)). Stagger sequence (0-8nt) was included in P5 and 8bp uniquely barcoded sequence in P7. Primers were synthesized through Integrated DNA Technologies (IDT), and each primer was PAGE purified. 32 PCR reactions were set up for each condition. Each 100ul PCR reaction consists of roughly 5ug of gDNA, 5ul of each 10uM P5 and P7. ExTaq DNA Polymerase (TaKaRa, Cat. RR001A) was used to amplify the amplicon. PCR Thermal Cycler Parameters set as Initial at 95oC for 1min; followed by 24 cycles of Denaturation at 94oC for 30 seconds, Annealing at 52.5oC for 30 seconds, Extension at 72oC for 30 seconds. A final Elongation at 72oC for 10 minutes. 285bp-293bp PCR products were expected (Supplementary Figure [12](#) A). PCR products within the same condition were pooled and purified using SPRIselect beads (Beckman Coulter, Cat. B23318). Purified Illumina libraries were quantitated on Qubit, and the quality of the library was analyzed on Bio-analyzer using High Sensitivity DNA Chip. A single approximate 285bp peak was expected. (Supplementary Figure [12](#) B). Final Illumina library samples were sequenced on Nova-seq 6000. Samples were pooled and loaded on an SP flow cell, along with a 20% PhiX control v3 library spike-in.

## Code and data availability

The code and data to reproduce all the analyses in this work are available in <https://github.com/greenelab/phenoplier>.

# References

---

1. **Relaxed purifying selection and possibly high rate of adaptation in primate lineage-specific genes.**  
James J Cai, Dmitri A Petrov  
*Genome biology and evolution* (2010-07-12) <https://www.ncbi.nlm.nih.gov/pubmed/20624743>  
DOI: [10.1093/gbe/evq019](https://doi.org/10.1093/gbe/evq019) · PMID: [20624743](https://pubmed.ncbi.nlm.nih.gov/20624743/) · PMCID: [PMC2997544](https://pmc.ncbi.nlm.nih.gov/pmcid/PMC2997544/)
2. **Elevated rates of protein secretion, evolution, and disease among tissue-specific genes.**  
Eitan E Winter, Leo Goodstadt, Chris P Ponting  
*Genome research* (2004-01) <https://www.ncbi.nlm.nih.gov/pubmed/14707169>  
DOI: [10.1101/gr.1924004](https://doi.org/10.1101/gr.1924004) · PMID: [14707169](https://pubmed.ncbi.nlm.nih.gov/14707169/) · PMCID: [PMC314278](https://pmc.ncbi.nlm.nih.gov/pmcid/PMC314278/)
3. **A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes**  
Kasper Lage, Niclas Tue Hansen, EOlof Karlberg, Aron C Eklund, Francisco S Roque, Patricia K Donahoe, Zoltan Szallasi, Thomas Skøt Jensen, Søren Brunak  
*Proceedings of the National Academy of Sciences* (2008-12-30) <https://doi.org/d5qcv9>  
DOI: [10.1073/pnas.0810772105](https://doi.org/10.1073/pnas.0810772105) · PMID: [19104045](https://pubmed.ncbi.nlm.nih.gov/19104045/) · PMCID: [PMC2606902](https://pmc.ncbi.nlm.nih.gov/pmcid/PMC2606902/)
4. **The GTEx Consortium atlas of genetic regulatory effects across human tissues** *Science* (2020-09-10) <https://doi.org/ghbnhr>  
DOI: [10.1126/science.aaz1776](https://doi.org/10.1126/science.aaz1776) · PMID: [32913098](https://pubmed.ncbi.nlm.nih.gov/32913098/) · PMCID: [PMC7737656](https://pmc.ncbi.nlm.nih.gov/pmcid/PMC7737656/)
5. **Index and biological spectrum of human DNase I hypersensitive sites**  
Wouter Meuleman, Alexander Muratov, Eric Rynes, Jessica Halow, Kristen Lee, Daniel Bates, Morgan Diegel, Douglas Dunn, Fidencio Neri, Athanasios Teodosiadis, ... John Stamatoyannopoulos  
*Nature* (2020-07-29) <https://doi.org/gg6dhp>  
DOI: [10.1038/s41586-020-2559-3](https://doi.org/10.1038/s41586-020-2559-3) · PMID: [32728217](https://pubmed.ncbi.nlm.nih.gov/32728217/) · PMCID: [PMC7422677](https://pmc.ncbi.nlm.nih.gov/pmcid/PMC7422677/)
6. **Mechanisms of tissue and cell-type specificity in heritable traits and diseases**  
Idan Hekselman, Esti Yeger-Lotem  
*Nature Reviews Genetics* (2020-01-08) <https://doi.org/ggkx9v>  
DOI: [10.1038/s41576-019-0200-9](https://doi.org/10.1038/s41576-019-0200-9) · PMID: [31913361](https://pubmed.ncbi.nlm.nih.gov/31913361/)
7. **The support of human genetic evidence for approved drug indications**  
Matthew R Nelson, Hannah Tipney, Jeffery L Painter, Judong Shen, Paola Nicoletti, Yufeng Shen, Aris Floratos, Pak Chung Sham, Mulin Jun Li, Junwen Wang, ... Philippe Sanseau  
*Nature Genetics* (2015-06-29) <https://doi.org/f3mn52>  
DOI: [10.1038/ng.3314](https://doi.org/10.1038/ng.3314) · PMID: [26121088](https://pubmed.ncbi.nlm.nih.gov/26121088/)
8. **Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval**  
Emily A King, JWade Davis, Jacob F Degner  
*PLOS Genetics* (2019-12-12) <https://doi.org/gg957r>  
DOI: [10.1371/journal.pgen.1008489](https://doi.org/10.1371/journal.pgen.1008489) · PMID: [31830040](https://pubmed.ncbi.nlm.nih.gov/31830040/) · PMCID: [PMC6907751](https://pmc.ncbi.nlm.nih.gov/pmcid/PMC6907751/)
9. **An integrated encyclopedia of DNA elements in the human genome** *Nature* (2012-09) <https://doi.org/bg9d>  
DOI: [10.1038/nature11247](https://doi.org/10.1038/nature11247) · PMID: [22955616](https://pubmed.ncbi.nlm.nih.gov/22955616/) · PMCID: [PMC3439153](https://pmc.ncbi.nlm.nih.gov/pmcid/PMC3439153/)
10. **Integrative analysis of 111 reference human epigenomes**

Anshul Kundaje, Wouter Meuleman, Jason Ernst, Misha Bilenky, Angela Yen, Alireza Heravi-Moussavi, Pouya Kheradpour, Zhizhuo Zhang, Jianrong Wang, ... Manolis Kellis

*Nature* (2015-02-18) <https://doi.org/f62jpn>

DOI: [10.1038/nature14248](https://doi.org/10.1038/nature14248) · PMID: [25693563](https://pubmed.ncbi.nlm.nih.gov/25693563/) · PMCID: [PMC4530010](https://pubmed.ncbi.nlm.nih.gov/PMC4530010/)

11. **An atlas of active enhancers across human cell types and tissues**

Robin Andersson, Claudia Gebhard, Irene Miguel-Escalada, Ilka Hoof, Jette Bornholdt, Mette Boyd, Yun Chen, Xiaobei Zhao, Christian Schmidl, ... Albin Sandelin

*Nature* (2014-03) <https://doi.org/r35>

DOI: [10.1038/nature12787](https://doi.org/10.1038/nature12787) · PMID: [24670763](https://pubmed.ncbi.nlm.nih.gov/24670763/) · PMCID: [PMC5215096](https://pubmed.ncbi.nlm.nih.gov/PMC5215096/)

12. **Regulatory genomic circuitry of human disease loci by integrative epigenomics**

Carles A Boix, Benjamin T James, Yongjin P Park, Wouter Meuleman, Manolis Kellis

*Nature* (2021-02-03) <https://doi.org/ghzkhr>

DOI: [10.1038/s41586-020-03145-z](https://doi.org/10.1038/s41586-020-03145-z) · PMID: [33536621](https://pubmed.ncbi.nlm.nih.gov/33536621/) · PMCID: [PMC7875769](https://pubmed.ncbi.nlm.nih.gov/PMC7875769/)

13. **The Post-GWAS Era: From Association to Function**

Michael D Gallagher, Alice S Chen-Plotkin

*The American Journal of Human Genetics* (2018-05) <https://doi.org/gdmftd>

DOI: [10.1016/j.ajhg.2018.04.002](https://doi.org/10.1016/j.ajhg.2018.04.002) · PMID: [29727686](https://pubmed.ncbi.nlm.nih.gov/29727686/) · PMCID: [PMC5986732](https://pubmed.ncbi.nlm.nih.gov/PMC5986732/)

14. **Reproducible RNA-seq analysis using recount2**

Leonardo Collado-Torres, Abhinav Nellore, Kai Kammers, Shannon E Ellis, Margaret A Taub, Kasper D Hansen, Andrew E Jaffe, Ben Langmead, Jeffrey T Leek

*Nature Biotechnology* (2017-04) <https://doi.org/gf75hp>

DOI: [10.1038/nbt.3838](https://doi.org/10.1038/nbt.3838) · PMID: [28398307](https://pubmed.ncbi.nlm.nih.gov/28398307/) · PMCID: [PMC6742427](https://pubmed.ncbi.nlm.nih.gov/PMC6742427/)

15. **Massive mining of publicly available RNA-seq data from human and mouse**

Alexander Lachmann, Denis Torre, Alexandra B Keenan, Kathleen M Jagodnik, Hoyjin J Lee, Lily Wang, Moshe C Silverstein, Avi Ma'ayan

*Nature Communications* (2018-04-10) <https://doi.org/gc92dr>

DOI: [10.1038/s41467-018-03751-6](https://doi.org/10.1038/s41467-018-03751-6) · PMID: [29636450](https://pubmed.ncbi.nlm.nih.gov/29636450/) · PMCID: [PMC5893633](https://pubmed.ncbi.nlm.nih.gov/PMC5893633/)

16. **Identification of therapeutic targets from genetic association studies using hierarchical component analysis**

Hao-Chih Lee, Osamu Ichikawa, Benjamin S Glicksberg, Aparna A Divaraniya, Christine E Becker, Pankaj Agarwal, Joel T Dudley

*BioData Mining* (2020-06-17) <https://doi.org/gjp5pf>

DOI: [10.1186/s13040-020-00216-9](https://doi.org/10.1186/s13040-020-00216-9) · PMID: [32565911](https://pubmed.ncbi.nlm.nih.gov/32565911/) · PMCID: [PMC7301559](https://pubmed.ncbi.nlm.nih.gov/PMC7301559/)

17. **Novel Variance-Component TWAS method for studying complex human diseases with applications to Alzheimer's dementia**

Shizhen Tang, Aron S Buchman, Philip L De Jager, David A Bennett, Michael P Epstein, Jingjing Yang

*PLOS Genetics* (2021-04-02) <https://doi.org/gjpr3>

DOI: [10.1371/journal.pgen.1009482](https://doi.org/10.1371/journal.pgen.1009482) · PMID: [33798195](https://pubmed.ncbi.nlm.nih.gov/33798195/) · PMCID: [PMC8046351](https://pubmed.ncbi.nlm.nih.gov/PMC8046351/)

18. **Integrative approaches for large-scale transcriptome-wide association studies**

Alexander Gusev, Arthur Ko, Huwenbo Shi, Gaurav Bhatia, Wonil Chung, Brenda WJH Penninx, Rick Jansen, Eco JC de Geus, Dorret I Boomsma, Fred A Wright, ... Bogdan Pasaniuc

*Nature Genetics* (2016-02-08) <https://doi.org/f3vf4p>

DOI: [10.1038/ng.3506](https://doi.org/10.1038/ng.3506) · PMID: [26854917](https://pubmed.ncbi.nlm.nih.gov/26854917/) · PMCID: [PMC4767558](https://pubmed.ncbi.nlm.nih.gov/PMC4767558/)

19. **Integrating predicted transcriptome from multiple tissues improves association detection**

- Alvaro N Barbeira, Milton Pividori, Jiamao Zheng, Heather E Wheeler, Dan L Nicolae, Hae Kyung Im  
*PLOS Genetics* (2019-01-22) <https://doi.org/ghs8vx>  
DOI: [10.1371/journal.pgen.1007889](https://doi.org/10.1371/journal.pgen.1007889) · PMID: [30668570](#) · PMCID: [PMC6358100](#)
20. **A gene-based association method for mapping traits using reference transcriptome data**  
Eric R Gamazon, Heather E Wheeler, Kaanan P Shah, Sahar V Mozaffari, Keston Aquino-Michaels, Robert J Carroll, Anne E Eyler, Joshua C Denny, Dan L Nicolae, Nancy J Cox, ...  
*Nature Genetics* (2015-08-10) <https://doi.org/f7p9zv>  
DOI: [10.1038/ng.3367](https://doi.org/10.1038/ng.3367) · PMID: [26258848](#) · PMCID: [PMC4552594](#)
21. **Integrating Gene Expression with Summary Association Statistics to Identify Genes Associated with 30 Complex Traits**  
Nicholas Mancuso, Huwenbo Shi, Pagé Goddard, Gleb Kichaev, Alexander Gusev, Bogdan Pasaniuc  
*The American Journal of Human Genetics* (2017-03) <https://doi.org/f9wvsg>  
DOI: [10.1016/j.ajhg.2017.01.031](https://doi.org/10.1016/j.ajhg.2017.01.031) · PMID: [28238358](#) · PMCID: [PMC5339290](#)
22. **Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types**  
Hilary K Finucane, Yakir A Reshef, Verner Anttila, Kamil Slowikowski, Alexander Gusev, Andrea Byrnes, Steven Gazal, Po-Ru Loh, Caleb Lareau, Noam Shreshet, ...  
*Nature Genetics* (2018-04) <https://doi.org/gdfjqt>  
DOI: [10.1038/s41588-018-0081-4](https://doi.org/10.1038/s41588-018-0081-4) · PMID: [29632380](#) · PMCID: [PMC5896795](#)
23. **Integrating Autoimmune Risk Loci with Gene-Expression Data Identifies Specific Pathogenic Immune Cell Subsets**  
Xinli Hu, Hyun Kim, Eli Stahl, Robert Plenge, Mark Daly, Soumya Raychaudhuri  
*The American Journal of Human Genetics* (2011-10) <https://doi.org/fphgp4>  
DOI: [10.1016/j.ajhg.2011.09.002](https://doi.org/10.1016/j.ajhg.2011.09.002) · PMID: [21963258](#) · PMCID: [PMC3188838](#)
24. **SNPsea: an algorithm to identify cell types, tissues and pathways affected by risk loci**  
Kamil Slowikowski, Xinli Hu, Soumya Raychaudhuri  
*Bioinformatics* (2014-05-10) <https://doi.org/f6j6v3>  
DOI: [10.1093/bioinformatics/btu326](https://doi.org/10.1093/bioinformatics/btu326) · PMID: [24813542](#) · PMCID: [PMC4147889](#)
25. **Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine**  
Padhraig Gormley, Verner Anttila, Bendik S Winsvold, Priit Palta, Tonus Esko, Tune H Pers, Kai-How Farh, Ester Cuenca-Leon, Mikko Muona, ... Aarno Palotie  
*Nature Genetics* (2016-06-20) <https://doi.org/bmzx>  
DOI: [10.1038/ng.3598](https://doi.org/10.1038/ng.3598) · PMID: [27322543](#) · PMCID: [PMC5331903](#)
26. **Biological interpretation of genome-wide association studies using predicted gene functions**  
Tune H Pers, Juha M Karjalainen, Yinglong Chan, Harm-Jan Westra, Andrew R Wood, Jian Yang, Julian C Lui, Sailaja Vedantam, Stefan Gustafsson, ... Lude Franke  
*Nature Communications* (2015-01-19) <https://doi.org/f3mwhd>  
DOI: [10.1038/ncomms6890](https://doi.org/10.1038/ncomms6890) · PMID: [25597830](#) · PMCID: [PMC4420238](#)
27. **Estimating the causal tissues for complex traits and diseases**  
Halit Onken, Andrew A Brown, Olivier Delaneau, Nikolaos I Panousis, Alexandra C Nica, Emmanouil T Dermitzakis  
*Nature Genetics* (2017-10-23) <https://doi.org/ggr72>  
DOI: [10.1038/ng.3981](https://doi.org/10.1038/ng.3981) · PMID: [29058715](#)

28. **A global overview of pleiotropy and genetic architecture in complex traits**  
Kyoko Watanabe, Sven Stringer, Oleksandr Frei, Maša Umićević Mirkov, Christiaan de Leeuw, Tinca JC Polderman, Sophie van der Sluis, Ole A Andreassen, Benjamin M Neale, Danielle Posthuma  
*Nature Genetics* (2019-08-19) <https://doi.org/ggr84r>  
DOI: [10.1038/s41588-019-0481-0](https://doi.org/10.1038/s41588-019-0481-0) · PMID: [31427789](#)
29. **Detection and interpretation of shared genetic influences on 42 human traits**  
Joseph K Pickrell, Tomaz Berisa, Jimmy Z Liu, Laure Ségurel, Joyce Y Tung, David A Hinds  
*Nature Genetics* (2016-05-16) <https://doi.org/f8ssw4>  
DOI: [10.1038/ng.3570](https://doi.org/10.1038/ng.3570) · PMID: [27182965](#) · PMCID: [PMC5207801](#)
30. **An Expanded View of Complex Traits: From Polygenic to Omnipgenic**  
Evan A Boyle, Yang I Li, Jonathan K Pritchard  
*Cell* (2017-06) <https://doi.org/gcpgdz>  
DOI: [10.1016/j.cell.2017.05.038](https://doi.org/10.1016/j.cell.2017.05.038) · PMID: [28622505](#) · PMCID: [PMC5536862](#)
31. **Trans Effects on Gene Expression Can Drive Omnipgenic Inheritance**  
Xuanyao Liu, Yang I Li, Jonathan K Pritchard  
*Cell* (2019-05) <https://doi.org/gfz8bj>  
DOI: [10.1016/j.cell.2019.04.014](https://doi.org/10.1016/j.cell.2019.04.014) · PMID: [31051098](#) · PMCID: [PMC6553491](#)
32. **PhenomeXcan: Mapping the genome to the phenotype through the transcriptome**  
Milton Pividori, Padma S Rajagopal, Alvaro Barbeira, Yanyu Liang, Owen Melia, Lisa Bastarache, YoSon Park, GTEx Consortium, Xiaoquan Wen, Hae K Im  
*Science Advances* (2020-09-11) <https://doi.org/ghbvbf>  
DOI: [10.1126/sciadv.aba2083](https://doi.org/10.1126/sciadv.aba2083) · PMID: [32917697](#)
33. **A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles**  
Aravind Subramanian, Rajiv Narayan, Steven M Corsello, David D Peck, Ted E Natoli, Xiaodong Lu, Joshua Gould, John F Davis, Andrew A Tubelli, Jacob K Asiedu, ... Todd R Golub  
*Cell* (2017-11) <https://doi.org/cgwt>  
DOI: [10.1016/j.cell.2017.10.049](https://doi.org/10.1016/j.cell.2017.10.049) · PMID: [29195078](#) · PMCID: [PMC5990023](#)
34. **MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease**  
Jaclyn N Taroni, Peter C Grayson, Qiwen Hu, Sean Eddy, Matthias Kretzler, Peter A Merkel, Casey S Greene  
*Cell Systems* (2019-05) <https://doi.org/gf75g5>  
DOI: [10.1016/j.cels.2019.04.003](https://doi.org/10.1016/j.cels.2019.04.003) · PMID: [31121115](#) · PMCID: [PMC6538307](#)
35. **Pathway-level information extractor (PLIER) for gene expression data**  
Weiguang Mao, Elena Zaslavsky, Boris M Hartmann, Stuart C Sealfon, Maria Chikina  
*Nature Methods* (2019-06-27) <https://doi.org/gf75g6>  
DOI: [10.1038/s41592-019-0456-1](https://doi.org/10.1038/s41592-019-0456-1) · PMID: [31249421](#) · PMCID: [PMC7262669](#)
36. **The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future**  
Omri Gottesman, Helena Kuivaniemi, Gerard Tromp, WAndrew Faucett, Rongling Li, Teri A Manolio, Saskia C Sanderson, Joseph Kannry, Randi Zinberg, Melissa A Basford, ... Marc S Williams  
*Genetics in Medicine* (2013-10) <https://doi.org/f5dwbt>  
DOI: [10.1038/gim.2013.72](https://doi.org/10.1038/gim.2013.72) · PMID: [23743551](#) · PMCID: [PMC3795928](#)

37. **Multi-ancestry gene-trait connection landscape using electronic health record (EHR) linked biobank data**  
Binglan Li, Yogasudha Veturi, Anastasia Lucas, Yuki Bradford, Shefali S Verma, Anurag Verma, Joseph Park, Wei-Qi Wei, Qiping Feng, Bahram Namjou, ... Marylyn D Ritchie  
*Cold Spring Harbor Laboratory* (2021-10-26) <https://doi.org/gnbdnb>  
DOI: [10.1101/2021.10.21.21265225](https://doi.org/10.1101/2021.10.21.21265225)
38. **The UK Biobank resource with deep phenotyping and genomic data**  
Clare Bycroft, Colin Freeman, Desislava Petkova, Gavin Band, Lloyd T Elliott, Kevin Sharp, Allan Motyer, Damjan Vukcevic, Olivier Delaneau, Jared O'Connell, ... Jonathan Marchini  
*Nature* (2018-10) <https://doi.org/gfb7h2>  
DOI: [10.1038/s41586-018-0579-z](https://doi.org/10.1038/s41586-018-0579-z) · PMID: [30305743](https://pubmed.ncbi.nlm.nih.gov/30305743/) · PMCID: [PMC6786975](https://pubmed.ncbi.nlm.nih.gov/PMC6786975/)
39. **Finding function: evaluation methods for functional genomic data**  
Chad L Myers, Daniel R Barrett, Matthew A Hibbs, Curtis Huttenhower, Olga G Troyanskaya  
*BMC Genomics* (2006-07-25) <https://doi.org/fg6wnk>  
DOI: [10.1186/1471-2164-7-187](https://doi.org/10.1186/1471-2164-7-187) · PMID: [16869964](https://pubmed.ncbi.nlm.nih.gov/16869964/) · PMCID: [PMC1560386](https://pubmed.ncbi.nlm.nih.gov/PMC1560386/)
40. **The CAFA challenge reports improved protein function prediction and new functional annotations for hundreds of genes through experimental screens**  
Naihui Zhou, Yuxiang Jiang, Timothy R Bergquist, Alexandra J Lee, Balint Z Kacsoh, Alex W Crocker, Kimberley A Lewis, George Georghiou, Huy N Nguyen, Md Nafiz Hamid, ... Iddo Friedberg  
*Genome Biology* (2019-11-19) <https://doi.org/ggnxpz>  
DOI: [10.1186/s13059-019-1835-8](https://doi.org/10.1186/s13059-019-1835-8) · PMID: [31744546](https://pubmed.ncbi.nlm.nih.gov/31744546/) · PMCID: [PMC6864930](https://pubmed.ncbi.nlm.nih.gov/PMC6864930/)
41. **MAGMA: Generalized Gene-Set Analysis of GWAS Data**  
Christiaan A de Leeuw, Joris M Mooij, Tom Heskes, Danielle Posthuma  
*PLOS Computational Biology* (2015-04-17) <https://doi.org/gf92gp>  
DOI: [10.1371/journal.pcbi.1004219](https://doi.org/10.1371/journal.pcbi.1004219) · PMID: [25885710](https://pubmed.ncbi.nlm.nih.gov/25885710/) · PMCID: [PMC4401657](https://pubmed.ncbi.nlm.nih.gov/PMC4401657/)
42. **Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression**  
Etienne Becht, Nicolas A Giraldo, Laetitia Lacroix, Bénédicte Buttard, Nabila Elaroui, Florent Petitprez, Janick Selvès, Pierre Laurent-Puig, Catherine Sautès-Fridman, Wolf H Fridman, Aurélien de Reyniès  
*Genome Biology* (2016-10-20) <https://doi.org/f87sgf>  
DOI: [10.1186/s13059-016-1070-5](https://doi.org/10.1186/s13059-016-1070-5) · PMID: [27765066](https://pubmed.ncbi.nlm.nih.gov/27765066/) · PMCID: [PMC5073889](https://pubmed.ncbi.nlm.nih.gov/PMC5073889/)
43. **Fast gene set enrichment analysis**  
Gennady Korotkevich, Vladimir Sukhov, Nikolay Budin, Boris Shpak, Maxim N Artyomov, Alexey Sergushichev  
*Cold Spring Harbor Laboratory* (2016-06-20) <https://doi.org/gfpqhm>  
DOI: [10.1101/060012](https://doi.org/10.1101/060012)
44. **DrugBank 4.0: shedding new light on drug metabolism**  
Vivian Law, Craig Knox, Yannick Djoumbou, Tim Jewison, An Chi Guo, Yifeng Liu, Adam Maciejewski, David Arndt, Michael Wilson, Vanessa Neveu, ... David S Wishart  
*Nucleic Acids Research* (2013-11-06) <https://doi.org/f3mn6d>  
DOI: [10.1093/nar/gkt1068](https://doi.org/10.1093/nar/gkt1068) · PMID: [24203711](https://pubmed.ncbi.nlm.nih.gov/24203711/) · PMCID: [PMC3965102](https://pubmed.ncbi.nlm.nih.gov/PMC3965102/)
45. **Systematic integration of biomedical knowledge prioritizes drugs for repurposing**  
Daniel Scott Himmelstein, Antoine Lizee, Christine Hessler, Leo Brueggeman, Sabrina L Chen, Dexter Hadley, Ari Green, Pouya Khankhanian, Sergio E Baranzini  
*eLife* (2017-09-22) <https://doi.org/cdfk>

46. **Dhimmel/Lincs V2.0: Refined Consensus Signatures From Lincs L1000**  
Daniel Himmelstein, Leo Brueggeman, Sergio Baranzini  
*Zenodo* (2016-03-08) <https://doi.org/f3mqvr>  
DOI: [10.5281/zenodo.47223](https://doi.org/10.5281/zenodo.47223)
47. **Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease**  
Joel T Dudley, Marina Sirota, Mohan Shenoy, Reetesh K Pai, Silke Roedder, Annie P Chiang, Alex A Morgan, Minnie M Sarwal, Pankaj Jay Pasricha, Atul J Butte  
*Science Translational Medicine* (2011-08-17) <https://doi.org/bmh5ts>  
DOI: [10.1126/scitranslmed.3002648](https://doi.org/10.1126/scitranslmed.3002648) · PMID: [21849664](https://pubmed.ncbi.nlm.nih.gov/21849664/) · PMCID: [PMC3479650](https://pubmed.ncbi.nlm.nih.gov/PMC3479650/)
48. **Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data**  
Marina Sirota, Joel T Dudley, Jeewon Kim, Annie P Chiang, Alex A Morgan, Alejandro Sweet-Cordero, Julien Sage, Atul J Butte  
*Science Translational Medicine* (2011-08-17) <https://doi.org/c3fwxv>  
DOI: [10.1126/scitranslmed.3001318](https://doi.org/10.1126/scitranslmed.3001318) · PMID: [21849665](https://pubmed.ncbi.nlm.nih.gov/21849665/) · PMCID: [PMC3502016](https://pubmed.ncbi.nlm.nih.gov/PMC3502016/)
49. **Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry**  
Hon-Cheong So, Carlos Kwan-Long Chau, Wan-To Chiu, Kin-Sang Ho, Cho-Pong Lo, Stephanie Ho-Yue Yim, Pak-Chung Sham  
*Nature Neuroscience* (2017-08-14) <https://doi.org/gbrssh>  
DOI: [10.1038/nn.4618](https://doi.org/10.1038/nn.4618) · PMID: [28805813](https://pubmed.ncbi.nlm.nih.gov/28805813/)
50. **Dhimmel/Indications V1.0. Pharmacotherapydb: The Open Catalog Of Drug Therapies For Disease**  
Daniel S Himmelstein, Pouya Khankhanian, Christine S Hessler, Ari J Green, Sergio E Baranzini  
*Zenodo* (2016-03-15) <https://doi.org/f3mqwb>  
DOI: [10.5281/zenodo.47664](https://doi.org/10.5281/zenodo.47664)
51. **Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.**  
, William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub  
*The New England journal of medicine* (2011-11-15)  
<https://www.ncbi.nlm.nih.gov/pubmed/22085343>  
DOI: [10.1056/nejmoa1107579](https://doi.org/10.1056/nejmoa1107579) · PMID: [22085343](https://pubmed.ncbi.nlm.nih.gov/22085343/)
52. **Effects of extended-release niacin with laropiprant in high-risk patients.**  
, Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, ... Jane Armitage  
*The New England journal of medicine* (2014-07-17)  
<https://www.ncbi.nlm.nih.gov/pubmed/25014686>  
DOI: [10.1056/nejmoa1300955](https://doi.org/10.1056/nejmoa1300955) · PMID: [25014686](https://pubmed.ncbi.nlm.nih.gov/25014686/)
53. **Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.**  
Elvira D'Andrea, Spencer P Hey, Cherie L Ramirez, Aaron S Kesselheim  
*JAMA network open* (2019-04-05) <https://www.ncbi.nlm.nih.gov/pubmed/30977858>  
DOI: [10.1001/jamanetworkopen.2019.2224](https://doi.org/10.1001/jamanetworkopen.2019.2224) · PMID: [30977858](https://pubmed.ncbi.nlm.nih.gov/30977858/) · PMCID: [PMC6481429](https://pubmed.ncbi.nlm.nih.gov/PMC6481429/)
54. **Mechanism of Action of Niacin**

Vaijinath S Kamanna, Moti L Kashyap  
*The American Journal of Cardiology* (2008-04) <https://doi.org/c8zwdt>  
DOI: [10.1016/j.amjcard.2008.02.029](https://doi.org/10.1016/j.amjcard.2008.02.029) · PMID: [18375237](#)

55. **Niacin: an old lipid drug in a new NAD<sup>+</sup> dress**  
Mario Romani, Dina Carina Hofer, Elena Katsyuba, Johan Auwerx  
*Journal of Lipid Research* (2019-04) <https://doi.org/gipjft>  
DOI: [10.1194/jlr.s092007](https://doi.org/10.1194/jlr.s092007) · PMID: [30782960](#) · PMCID: [PMC6446705](#)
56. **The therapeutic role of niacin in dyslipidemia management.**  
William E Boden, Mandeep S Sidhu, Peter P Toth  
*Journal of cardiovascular pharmacology and therapeutics* (2013-12-20)  
<https://www.ncbi.nlm.nih.gov/pubmed/24363242>  
DOI: [10.1177/1074248413514481](https://doi.org/10.1177/1074248413514481) · PMID: [24363242](#)
57. **High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.**  
S Tuteja, DJ Rader  
*Clinical pharmacology and therapeutics* (2014-04-08)  
<https://www.ncbi.nlm.nih.gov/pubmed/24713591>  
DOI: [10.1038/clpt.2014.79](https://doi.org/10.1038/clpt.2014.79) · PMID: [24713591](#)
58. **The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target**  
S OFFERMANNS  
*Trends in Pharmacological Sciences* (2006-07) <https://doi.org/fgb4tr>  
DOI: [10.1016/j.tips.2006.05.008](https://doi.org/10.1016/j.tips.2006.05.008) · PMID: [16766048](#)
59. **Langerhans Cells Release Prostaglandin D2 in Response to Nicotinic Acid**  
Dominique Maciejewski-Lenoir, Jeremy G Richman, Yaron Hakak, Ibragim Gaidarov, Dominic P Behan, Daniel T Connolly  
*Journal of Investigative Dermatology* (2006-12) <https://doi.org/dgxg75>  
DOI: [10.1038/sj.jid.5700586](https://doi.org/10.1038/sj.jid.5700586) · PMID: [17008871](#)
60. **Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells**  
Martina Lukasova, Camille Malaval, Andreas Gille, Jukka Kero, Stefan Offermanns  
*Journal of Clinical Investigation* (2011-03-01) <https://doi.org/cqftcq>  
DOI: [10.1172/jci41651](https://doi.org/10.1172/jci41651) · PMID: [21317532](#) · PMCID: [PMC3048854](#)
61. **Role of HDL, ABCA1, and ABCG1 Transporters in Cholesterol Efflux and Immune Responses**  
Laurent Yvan-Charvet, Nan Wang, Alan R Tall  
*Arteriosclerosis, Thrombosis, and Vascular Biology* (2010-02) <https://doi.org/ds23w6>  
DOI: [10.1161/atvaha.108.179283](https://doi.org/10.1161/atvaha.108.179283) · PMID: [19797709](#) · PMCID: [PMC2812788](#)
62. **Shared and organism-specific host responses to childhood diarrheal diseases revealed by whole blood transcript profiling**  
Hannah A DeBerg, Mussaret B Zaidi, Matthew C Altman, Prasong Khaenam, Vivian H Gersuk, Freddy D Campos, Iza Perez-Martinez, Mario Meza-Segura, Damien Chaussabel, Jacques Banchereau, ... Peter S Linsley  
*PLOS ONE* (2018-01-29) <https://doi.org/gcwgr>  
DOI: [10.1371/journal.pone.0192082](https://doi.org/10.1371/journal.pone.0192082) · PMID: [29377961](#) · PMCID: [PMC5788382](#)
63. **Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis**

Peter S Linsley, Cate Speake, Elizabeth Whalen, Damien Chaussabel  
*PLoS ONE* (2014-10-14) <https://doi.org/gk9k8s>  
DOI: [10.1371/journal.pone.0109760](https://doi.org/10.1371/journal.pone.0109760) · PMID: [25314013](#) · PMCID: [PMC4196925](#)

64. **The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression**  
T Hung, GA Pratt, B Sundararaman, MJ Townsend, C Chaivorapol, T Bhangale, RR Graham, W Ortmann, LA Criswell, GW Yeo, TW Behrens  
*Science* (2015-10-23) <https://doi.org/f7vs67>  
DOI: [10.1126/science.aac7442](https://doi.org/10.1126/science.aac7442) · PMID: [26382853](#) · PMCID: [PMC4691329](#)
65. **Homo sapiens (ID 258384) - BioProject - NCBI**  
<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA258384>
66. **Identification of Genes Critical for Resistance to Infection by West Nile Virus Using RNA-Seq Analysis**  
Feng Qian, Lisa Chung, Wei Zheng, Vincent Bruno, Roger Alexander, Zhong Wang, Xiaomei Wang, Sebastian Kurscheid, Hongyu Zhao, Erol Fikrig, ... Ruth Montgomery  
*Viruses* (2013-07-08) <https://doi.org/f49d7g>  
DOI: [10.3390/v5071664](https://doi.org/10.3390/v5071664) · PMID: [23881275](#) · PMCID: [PMC3738954](#)
67. **Mycobacterial infection induces a specific human innate immune response**  
John D Blischak, Ludovic Tailleux, Amy Mitrano, Luis B Barreiro, Yoav Gilad  
*Scientific Reports* (2015-11-20) <https://doi.org/f7zk5c>  
DOI: [10.1038/srep16882](https://doi.org/10.1038/srep16882) · PMID: [26586179](#) · PMCID: [PMC4653619](#)
68. **Niacin Inhibits Apoptosis and Rescues Premature Ovarian Failure**  
Shufang Wang, Min Sun, Ling Yu, Yixuan Wang, Yuanqing Yao, Deqing Wang  
*Cellular Physiology and Biochemistry* (2018) <https://doi.org/gfqvcq>  
DOI: [10.1159/000495051](https://doi.org/10.1159/000495051) · PMID: [30415247](#)
69. **Chronic niacin administration ameliorates ovulation, histological changes in the ovary and adiponectin concentrations in a rat model of polycystic ovary syndrome**  
Negin Asadi, Mahin Izadi, Ali Aflatounian, Mansour Esmaeili-Dehaj, Mohammad Ebrahim Rezvani, Zeinab Hafizi  
*Reproduction, Fertility and Development* (2021) <https://doi.org/gjpjkt>  
DOI: [10.1071/rd20306](https://doi.org/10.1071/rd20306) · PMID: [33751926](#)
70. **Clustering trees: a visualization for evaluating clusterings at multiple resolutions**  
Luke Zappia, Alicia Oshlack  
*GigaScience* (2018-07-01) <https://doi.org/gfzqf5>  
DOI: [10.1093/gigascience/giy083](https://doi.org/10.1093/gigascience/giy083) · PMID: [30010766](#) · PMCID: [PMC6057528](#)
71. **Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study.**  
Darryl P Leong, Koon K Teo, Sumathy Rangarajan, Patricio Lopez-Jaramillo, Alvaro Avezum, Andres Orlandini, Pamela Seron, Suad H Ahmed, Annika Rosengren, Roya Kelishadi, ...  
*Lancet (London, England)* (2015-05-13) <https://www.ncbi.nlm.nih.gov/pubmed/25982160>  
DOI: [10.1016/s0140-6736\(14\)62000-6](https://doi.org/10.1016/s0140-6736(14)62000-6) · PMID: [25982160](#)
72. **Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis**  
Noa Novershtern, Aravind Subramanian, Lee N Lawton, Raymond H Mak, WNicholas Haining, Marie E McConkey, Naomi Habib, Nir Yosef, Cindy Y Chang, Tal Shay, ... Benjamin L Ebert  
*Cell* (2011-01) <https://doi.org/cf5k92>

73. **CD19<sup>+</sup>/CD5<sup>+</sup> Cells as Indicators of Preeclampsia**  
Federico Jensen, Gerd Wallukat, Florian Herse, Oliver Budner, Tarek El-Mousleh, Serban-Dan Costa, Ralf Dechend, Ana Claudia Zenclussen  
*Hypertension* (2012-04) <https://doi.org/gj36rs>  
DOI: [10.1161/hypertensionaha.111.188276](https://doi.org/10.1161/hypertensionaha.111.188276) · PMID: [22353610](https://pubmed.ncbi.nlm.nih.gov/22353610/)
74. **Conditional and interaction gene-set analysis reveals novel functional pathways for blood pressure**  
Christiaan A de Leeuw, Sven Stringer, Ilona A Dekkers, Tom Heskes, Danielle Posthumus  
*Nature Communications* (2018-09-14) <https://doi.org/gd6d85>  
DOI: [10.1038/s41467-018-06022-6](https://doi.org/10.1038/s41467-018-06022-6) · PMID: [30218068](https://pubmed.ncbi.nlm.nih.gov/30218068/) · PMCID: [PMC6138636](https://pubmed.ncbi.nlm.nih.gov/PMC6138636/)
75. **Estrogen and hypertension**  
Muhammad S Ashraf, Wanpen Vongpatanasin  
*Current Hypertension Reports* (2006-09) <https://doi.org/d638rf>  
DOI: [10.1007/s11906-006-0080-1](https://doi.org/10.1007/s11906-006-0080-1) · PMID: [16965722](https://pubmed.ncbi.nlm.nih.gov/16965722/)
76. **Depression as a predictor for coronary heart disease. a review and meta-analysis.**  
Reiner Rugulies  
*American journal of preventive medicine* (2002-07)  
<https://www.ncbi.nlm.nih.gov/pubmed/12093424>  
DOI: [10.1016/s0749-3797\(02\)00439-7](https://doi.org/10.1016/s0749-3797(02)00439-7) · PMID: [12093424](https://pubmed.ncbi.nlm.nih.gov/12093424/)
77. **Mental Disorders Across the Adult Life Course and Future Coronary Heart Disease**  
Catharine R Gale, GDavid Batty, David PJ Osborn, Per Tynelius, Finn Rasmussen  
*Circulation* (2014-01-14) <https://doi.org/qm4>  
DOI: [10.1161/circulationaha.113.002065](https://doi.org/10.1161/circulationaha.113.002065) · PMID: [24190959](https://pubmed.ncbi.nlm.nih.gov/24190959/) · PMCID: [PMC4107269](https://pubmed.ncbi.nlm.nih.gov/PMC4107269/)
78. **Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014**  
Joseph F Hayes, Louise Marston, Kate Walters, Michael B King, David PJ Osborn  
*British Journal of Psychiatry* (2017-09) <https://doi.org/gbwcxj>  
DOI: [10.1192/bjp.bp.117.202606](https://doi.org/10.1192/bjp.bp.117.202606) · PMID: [28684403](https://pubmed.ncbi.nlm.nih.gov/28684403/) · PMCID: [PMC5579328](https://pubmed.ncbi.nlm.nih.gov/PMC5579328/)
79. **Getting to the Heart of Alzheimer Disease**  
Joshua M Tublin, Jeremy M Adelstein, Federica del Monte, Colin K Combs, Loren E Wold  
*Circulation Research* (2019-01-04) <https://doi.org/gjzjgg>  
DOI: [10.1161/circresaha.118.313563](https://doi.org/10.1161/circresaha.118.313563) · PMID: [30605407](https://pubmed.ncbi.nlm.nih.gov/30605407/) · PMCID: [PMC6319653](https://pubmed.ncbi.nlm.nih.gov/PMC6319653/)
80. **The overlap between vascular disease and Alzheimer's disease - lessons from pathology**  
Johannes Attems, Kurt A Jellinger  
*BMC Medicine* (2014-11-11) <https://doi.org/f6pj4>  
DOI: [10.1186/s12916-014-0206-2](https://doi.org/10.1186/s12916-014-0206-2) · PMID: [25385447](https://pubmed.ncbi.nlm.nih.gov/25385447/) · PMCID: [PMC4226890](https://pubmed.ncbi.nlm.nih.gov/PMC4226890/)
81. **Cardiovascular Risk Factors for Alzheimer's Disease**  
Clive Rosendorff, Michal S Beeri, Jeremy M Silverman  
*The American Journal of Geriatric Cardiology* (2007-03) <https://doi.org/bpfw5d>  
DOI: [10.1111/j.1076-7460.2007.06696.x](https://doi.org/10.1111/j.1076-7460.2007.06696.x) · PMID: [17483665](https://pubmed.ncbi.nlm.nih.gov/17483665/)
82. **Reverse cholesterol transport and cholesterol efflux in atherosclerosis**  
R Ohashi, H Mu, X Wang, Q Yao, C Chen  
*QJM: An International Journal of Medicine* (2005-10-28) <https://doi.org/dn2fgt>  
DOI: [10.1093/qjmed/hci136](https://doi.org/10.1093/qjmed/hci136) · PMID: [16258026](https://pubmed.ncbi.nlm.nih.gov/16258026/)

83. **Lipid and Lipoprotein Metabolism in Microglia**  
Bailey A Loving, Kimberley D Bruce  
*Frontiers in Physiology* (2020-04-28) <https://doi.org/gk92xd>  
DOI: [10.3389/fphys.2020.00393](https://doi.org/10.3389/fphys.2020.00393) · PMID: [32411016](https://pubmed.ncbi.nlm.nih.gov/32411016/) · PMCID: [PMC7198855](https://pubmed.ncbi.nlm.nih.gov/PMC7198855/)
84. **recount3: summaries and queries for large-scale RNA-seq expression and splicing**  
Christopher Wilks, Shijie C Zheng, Feng Yong Chen, Rone Charles, Brad Solomon, Jonathan P Ling, Eddie Luidy Imada, David Zhang, Lance Joseph, Jeffrey T Leek, ... Ben Langmead  
*Cold Spring Harbor Laboratory* (2021-05-23) <https://doi.org/gj7cmq>  
DOI: [10.1101/2021.05.21.445138](https://doi.org/10.1101/2021.05.21.445138)
85. **Opportunities and challenges for transcriptome-wide association studies**  
Michael Wainberg, Nasa Sinnott-Armstrong, Nicholas Mancuso, Alvaro N Barbeira, David A Knowles, David Golan, Raili Ermel, Arno Ruusalepp, Thomas Quertermous, Ke Hao, ... Anshul Kundaje  
*Nature Genetics* (2019-03-29) <https://doi.org/gf3hmr>  
DOI: [10.1038/s41588-019-0385-z](https://doi.org/10.1038/s41588-019-0385-z) · PMID: [30926968](https://pubmed.ncbi.nlm.nih.gov/30926968/) · PMCID: [PMC6777347](https://pubmed.ncbi.nlm.nih.gov/PMC6777347/)
86. **Probabilistic colocalization of genetic variants from complex and molecular traits: promise and limitations**  
Abhay Hukku, Milton Pividori, Francesca Luca, Roger Pique-Regi, Hae Kyung Im, Xiaoquan Wen  
*The American Journal of Human Genetics* (2021-01) <https://doi.org/gj58gg>  
DOI: [10.1016/j.ajhg.2020.11.012](https://doi.org/10.1016/j.ajhg.2020.11.012) · PMID: [33308443](https://pubmed.ncbi.nlm.nih.gov/33308443/) · PMCID: [PMC7820626](https://pubmed.ncbi.nlm.nih.gov/PMC7820626/)
87. **Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights**  
Alexander Gusev, Nicholas Mancuso, Hyejung Won, Maria Kousi, Hilary K Finucane, Yakir Reshef, Lingyun Song, Alexias Safi, Steven McCarroll, Benjamin M Neale, ...  
*Nature Genetics* (2018-04) <https://doi.org/gdfdf2>  
DOI: [10.1038/s41588-018-0092-1](https://doi.org/10.1038/s41588-018-0092-1) · PMID: [29632383](https://pubmed.ncbi.nlm.nih.gov/29632383/) · PMCID: [PMC5942893](https://pubmed.ncbi.nlm.nih.gov/PMC5942893/)
88. **Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology**  
Manuel A Ferreira, Judith M Vonk, Hansjörg Baurecht, Ingo Marenholz, Chao Tian, Joshua D Hoffman, Quinta Helmer, Annika Tillander, Vilhelmina Ullemar, ...  
*Nature Genetics* (2017-10-30) <https://doi.org/gchg62>  
DOI: [10.1038/ng.3985](https://doi.org/10.1038/ng.3985) · PMID: [29083406](https://pubmed.ncbi.nlm.nih.gov/29083406/) · PMCID: [PMC5989923](https://pubmed.ncbi.nlm.nih.gov/PMC5989923/)
89. **A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases**  
Zhaozhong Zhu, Phil H Lee, Mark D Chaffin, Wonil Chung, Po-Ru Loh, Quan Lu, David C Christiani, Liming Liang  
*Nature Genetics* (2018-05-21) <https://doi.org/gdpmtn>  
DOI: [10.1038/s41588-018-0121-0](https://doi.org/10.1038/s41588-018-0121-0) · PMID: [29785011](https://pubmed.ncbi.nlm.nih.gov/29785011/) · PMCID: [PMC5980765](https://pubmed.ncbi.nlm.nih.gov/PMC5980765/)
90. **Systematic tissue annotations of -omics samples by modeling unstructured metadata**  
Nathaniel T Hawkins, Marc Maldaver, Anna Yannakopoulos, Lindsay A Guare, Arjun Krishnan  
*Cold Spring Harbor Laboratory* (2021-05-11) <https://doi.org/gj2pkc>  
DOI: [10.1101/2021.05.10.443525](https://doi.org/10.1101/2021.05.10.443525)
91. **Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics**  
Alvaro N Barbeira, Scott P Dickinson, Rodrigo Bonazzola, Jiamao Zheng, Heather E Wheeler, Jason M Torres, Eric S Torstenson, Kaanan P Shah, Tzintzuni Garcia, ... Hae Kyung Im  
*Nature Communications* (2018-05-08) <https://doi.org/gdjvp5>  
DOI: [10.1038/s41467-018-03621-1](https://doi.org/10.1038/s41467-018-03621-1) · PMID: [29739930](https://pubmed.ncbi.nlm.nih.gov/29739930/) · PMCID: [PMC5940825](https://pubmed.ncbi.nlm.nih.gov/PMC5940825/)

92. **The Molecular Signatures Database Hallmark Gene Set Collection**  
Arthur Liberzon, Chet Birger, Helga Thorvaldsdóttir, Mahmoud Ghandi, Jill P Mesirov, Pablo Tamayo  
*Cell Systems* (2015-12) <https://doi.org/gf78hq>  
DOI: [10.1101/j.cels.2015.12.004](https://doi.org/10.1101/j.cels.2015.12.004) · PMID: [26771021](https://pubmed.ncbi.nlm.nih.gov/26771021/) · PMCID: [PMC4707969](https://pubmed.ncbi.nlm.nih.gov/PMC4707969/)
93. **Human Disease Ontology 2018 update: classification, content and workflow expansion**  
Lynn M Schriml, Elvira Mitraka, James Munro, Becky Tauber, Mike Schor, Lance Nickle, Victor Felix, Linda Jeng, Cynthia Bearer, Richard Lichenstein, ... Carol Greene  
*Nucleic Acids Research* (2018-11-08) <https://doi.org/ggx9wp>  
DOI: [10.1093/nar/gky1032](https://doi.org/10.1093/nar/gky1032) · PMID: [30407550](https://pubmed.ncbi.nlm.nih.gov/30407550/) · PMCID: [PMC6323977](https://pubmed.ncbi.nlm.nih.gov/PMC6323977/)
94. **Modeling sample variables with an Experimental Factor Ontology**  
James Malone, Ele Holloway, Tomasz Adamusiak, Misha Kapushesky, Jie Zheng, Nikolay Kolesnikov, Anna Zhukova, Alvis Brazma, Helen Parkinson  
*Bioinformatics* (2010-03-03) <https://doi.org/dsb6vt>  
DOI: [10.1093/bioinformatics/btq099](https://doi.org/10.1093/bioinformatics/btq099) · PMID: [20200009](https://pubmed.ncbi.nlm.nih.gov/20200009/) · PMCID: [PMC2853691](https://pubmed.ncbi.nlm.nih.gov/PMC2853691/)
95. **GitHub - EBISPORT/EFO-UKB-mappings**  
GitHub  
<https://github.com/EBISPORT/EFO-UKB-mappings>
96. **Comparing partitions**  
Lawrence Hubert, Phipps Arabie  
*Journal of Classification* (1985-12) <https://doi.org/bphmzh>  
DOI: [10.1007/bf01908075](https://doi.org/10.1007/bf01908075)
97. **Combining multiple clusterings using evidence accumulation**  
Ana LN Fred, Anil K Jain  
*IEEE Transactions on Pattern Analysis and Machine Intelligence* (2005-06) <https://doi.org/bsknv6>  
DOI: [10.1109/tpami.2005.113](https://doi.org/10.1109/tpami.2005.113) · PMID: [15943417](https://pubmed.ncbi.nlm.nih.gov/15943417/)
98. **Diversity control for improving the analysis of consensus clustering**  
Milton Pividori, Georgina Stegmayer, Diego H Milone  
*Information Sciences* (2016-09) <https://doi.org/ghtqbk>  
DOI: [10.1016/j.ins.2016.04.027](https://doi.org/10.1016/j.ins.2016.04.027)
99. **A Link-Based Approach to the Cluster Ensemble Problem**  
Natthakan Iam-On, Tossapon Boongoen, Simon Garrett, Chris Price  
*IEEE Transactions on Pattern Analysis and Machine Intelligence* (2011-12) <https://doi.org/cqgkh3>  
DOI: [10.1109/tpami.2011.84](https://doi.org/10.1109/tpami.2011.84) · PMID: [21576752](https://pubmed.ncbi.nlm.nih.gov/21576752/)
100. **Hybrid clustering solution selection strategy**  
Zhiwen Yu, Le Li, Yunjun Gao, Jane You, Jiming Liu, Hau-San Wong, Guoqiang Han  
*Pattern Recognition* (2014-10) <https://doi.org/ghtzwt>  
DOI: [10.1016/j.patcog.2014.04.005](https://doi.org/10.1016/j.patcog.2014.04.005)
101. **UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction**  
Leland McInnes, John Healy, James Melville  
*arXiv* (2020-09-21) <https://arxiv.org/abs/1802.03426>
102. **k-means++: the advantages of careful seeding**  
David Arthur, Sergei Vassilvitskii  
*Proceedings of the Eighteenth Annual ACM-SIAM Symposium on Discrete Algorithms* (2007)  
<http://ilpubs.stanford.edu:8090/778/1/2006-13.pdf>

103. **On Spectral Clustering: Analysis and an algorithm**  
Andrew Ng, Michael Jordan, Yair Weiss  
*Advances in Neural Information Processing Systems* (2001)  
<https://ai.stanford.edu/~ang/papers/nips01-spectral.pdf>
104. **A Density-Based Algorithm for Discovering Clusters in Large Spatial Databases with Noise**  
Martin Ester, Hans-Peter Kriegel, Jörg Sander, Xiaowei Xu  
*Proceedings of the Second International Conference on Knowledge Discovery and Data Mining* (1996) <https://www.aaai.org/Papers/KDD/1996/KDD96-037.pdf>
105. **Determination of Optimal Epsilon (Eps) Value on DBSCAN Algorithm to Clustering Data on Peatland Hotspots in Sumatra**  
Nadia Rahmah, Imas Sukaesih Sitanggang  
*IOP Conference Series: Earth and Environmental Science* (2016-01) <https://doi.org/gqr7z2>  
DOI: [10.1088/1755-1315/31/1/012012](https://doi.org/10.1088/1755-1315/31/1/012012)
106. **Avoiding common pitfalls when clustering biological data.**  
Tom Ronan, Zhijie Qi, Kristen M Naegle  
*Science signaling* (2016-06-14) <https://www.ncbi.nlm.nih.gov/pubmed/27303057>  
DOI: [10.1126/scisignal.aad1932](https://doi.org/10.1126/scisignal.aad1932) · PMID: [27303057](https://pubmed.ncbi.nlm.nih.gov/27303057/)
107. **Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.**  
John G Doench, Nicolo Fusi, Meagan Sullender, Mudra Hegde, Emma W Vaimberg, Katherine F Donovan, Ian Smith, Zuzana Tothova, Craig Wilen, Robert Orchard, ... David E Root  
*Nature biotechnology* (2016-01-18) <https://www.ncbi.nlm.nih.gov/pubmed/26780180>  
DOI: [10.1038/nbt.3437](https://doi.org/10.1038/nbt.3437) · PMID: [26780180](https://pubmed.ncbi.nlm.nih.gov/26780180/) · PMCID: [PMC4744125](https://pmcid.ncbi.nlm.nih.gov/pmcid/PMC4744125/)
108. **Homo sapiens (ID 232177) - BioProject - NCBI**  
<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA232177>

## Acknowledgements


---

Figure 1 was created with BioRender.com.


## Supplementary material

---


### CRISPR-screen



**Figure 8: EVOS Fluorescent Microscope Image Capture.** A. HepG2\_lentiV2\_Ctrl with no-viral transduction. B. HepG2\_lentiV2 with viral transduction.



**Figure 9: Fluorescence-Activated Cell Sorting Gate Setting.** A. HepG2\_UnStained WT. B. HepG2\_lentiV2 with viral transduction.



**Figure 10: Verification of sgRNA cassette and lentiV2 transgene.** A. 20nt sgRNA cassette was verified in lentiV2 transduced genomic DNA population, 163 bp PCR product obtained, while WT HepG2 didn't possess the cassette, thus, no PCR product. B. lentiviral-specific transgene WPRE was verified in lentiV2 transduced genomic DNA population, while no transduced WT didn't have the transgene, therefore, no 173 bp PCR product observed.

**Table 1. Primers for Generating Illumina Libraries**

P5/P7 flowcell attachment sequence

Illumina sequencing primer

Vector primer binding sequence

Stagger region / Barcode region

P5 primer :

5'AATGATACGGCACCACCGAGATCTACACTCTTCCCTACACGACGCTTCCGATCT[s]TTGTGGAAAGGACGAAACACCG

P7 primer:


5'CAAGCAGAAGACGGCATACGAGATNNNNNNNNTGACTGGAGTCAGACGTGCTTCCGATCTCCAATTCCCACCTCCTTCAGACCT

P5 Stagger Region sequences ([s])	
	Stagger Sequence to include in P5 primer, 5'-3'
P5 0 nt	
P5 1 nt	C
P5 2 nt	GC
P5 3 nt	AGC
P5 4 nt	CAAC
P5 6 nt	TGCACC
P5 7nt	ACGCAAC
P5 8nt	GAAGACCC


P7 barcode (index) sequences (NNNNNNNN )	
	Sequence to include in P7 primer, 5'-3'
P7-001	CGGTTCAA
P7-002	GCTGGATT
P7-003	TAACTCGG
P7-004	TAACAGTT
P7-005	ATACTCAA
P7-006	GCTGAGAA
P7-007	ATTGGAGG
P7-008	TAGTCTAA
P7-009	CGGTGACC

**Figure 11:**

### A. Construct For Illumina Library Generation



### B. 2100 expert\_High Sensitivity DNA Assay



**Figure 12: Illumina library generation.** A. Construct for generating illumina libraries. B. Final illumina library from HS DNA —showed a single ~285bp peak was generated.

## LV603

**Table 2:** Pathways aligned to LV603 from the MultiPLIER models.

Pathway	AUC	FDR
IRIS Neutrophil-Resting	0.91	4.51e-35
SVM Neutrophils	0.98	1.43e-09
PID IL8CXCR2 PATHWAY	0.81	7.04e-03
SIG PIP3 SIGNALING IN B LYMPHOCYTES	0.77	1.95e-02

**Table 3:** Significant trait associations of LV603 in PhenomeXcan.

Trait description	Sample size	Cases	FDR
Myeloid White Cell Count	173,480		3.63e-07
Sum Basophil Neutrophil Count	173,480		4.07e-07
Neutrophil Count	173,480		4.17e-07
Sum Neutrophil Eosinophil Count	173,480		4.72e-07
Granulocyte Count	173,480		5.16e-07
White Blood Cell Count	173,480		2.67e-06
Neutrophill count	349,856		1.58e-05
White blood cell (leukocyte) count	350,470		2.06e-05

**Table 4:** Significant trait associations of LV603 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
No significant associations				

## Gene modules enrichment for lipids gene-sets

**Table 5:** Gene modules (LVs) nominally enriched for the lipids-increasing gene-set from the CRISPR-screen ( $P < 0.01$ ). LVs significantly aligned with pathways (FDR  $< 0.05$ ) from the MultiPLIER models are shown in boldface.

Gene module	Lipids gene-set	Leading edge	p-value
<b>LV246</b>	increase	DGAT2, ACACA	0.0035
LV702	increase	ACACA, DGAT2	0.0046
<b>LV607</b>	increase	ACACA, DGAT2	0.0058
LV890	increase	ACACA, DGAT2	0.0067
<b>LV74</b>	increase	MBTPS1, DGAT2	0.0078
<b>LV865</b>	increase	ACACA, DGAT2	0.0092
LV841	increase	ACACA, DGAT2	0.0096

**Table 6:** Gene modules (LVs) nominally enriched for the lipids-decreasing gene-set from the CRISPR-screen ( $P < 0.01$ ). LVs significantly aligned with pathways (FDR  $< 0.05$ ) from the MultiPLIER models are shown in boldface.

Gene module	Lipids gene-set	Leading edge	p-value
LV520	decrease	FBXW7, TCF7L2	0.0006
LV801	decrease	UBE2J2, TCF7L2	0.0022
LV512	decrease	FBXW7, TCF7L2	0.0025
<b>LV612</b>	decrease	PTEN, FBXW7	0.0036
LV41	decrease	PCYT2, TCF7L2	0.0041
<b>LV838</b>	decrease	UBE2J2, TCF7L2	0.0070
LV302	decrease	TCF7L2, PTEN	0.0083
LV959	decrease	TCF7L2, PTEN	0.0092

## LV246

**Table 7:** Pathways aligned to LV246 from the MultiPLIER models.

Pathway	AUC	FDR
REACTOME FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM	0.89	3.97e-16
REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS	0.67	1.14e-08
REACTOME TRIGLYCERIDE BIOSYNTHESIS	0.86	6.52e-04
KEGG PYRUVATE METABOLISM	0.82	2.66e-03
KEGG PROPANOATE METABOLISM	0.83	4.27e-03

**Table 8:** Significant trait associations of LV246 in PhenomeXcan.

Trait description	Sample size	Cases	FDR
CH2DB NMR	24,154		1.05e-12
High cholesterol (self-reported)	361,141	43,957	7.78e-07
Ankle spacing width	206,589		2.06e-05
Ankle spacing width (right)	114,614		9.03e-05
HDL Cholesterol NMR	19,270		2.46e-04
Cholesterol lowering medication	193,148	24,247	2.54e-04
Ankle spacing width (left)	114,630		5.39e-04
Fasting Glucose	46,186		1.90e-03
Cholesterol lowering medication	165,340	38,057	6.74e-03
Pulse rate, automated reading	340,162		8.61e-03
Recent easy annoyance or irritability	117,483		1.04e-02
Treatment/medication code: simvastatin	361,141	40,921	1.11e-02
Pulse rate	118,850		1.19e-02
Mean platelet (thrombocyte) volume	350,470		1.37e-02
Duration of moderate activity	268,826		1.69e-02
LDL Cholesterol NMR	13,527		1.94e-02
Red blood cell (erythrocyte) distribution width	350,473		1.99e-02
Intra-ocular pressure, corneal-compensated (right)	76,630		2.63e-02
Heel bone mineral density (BMD) (right)	114,552		2.74e-02
Triglycerides NMR	21,559		3.47e-02
Heel bone mineral density T-score, automated (right)	114,614		3.75e-02
Heel quantitative ultrasound index, direct entry (right)	114,614		3.75e-02
Days/week of moderate physical activity 10+ minutes	343,943		4.85e-02
Ischaemic heart disease (wide definition)	361,194	20,857	4.97e-02

**Table 9:** Significant trait associations of LV246 in eMERGE.


Phecode	Trait description	Sample size	Cases	FDR
276.41	Acidosis	41,838	1,526	2.40e-03
276.4	Acid-base balance disorder	42,005	1,693	2.97e-03

## LV116

**Table 10:** Pathways aligned to LV116 from the MultiPLIER models.

Pathway	AUC	FDR
REACTOME INTERFERON SIGNALING	0.84	3.48e-09
SVM Macrophages M1	0.92	2.09e-05
REACTOME INTERFERON ALPHA BETA SIGNALING	0.94	3.36e-05
REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM	0.67	1.53e-04
IRIS DendriticCell-LPSstimulated	0.65	1.09e-03
KEGG CYTOSOLIC DNA SENSING PATHWAY	0.84	3.22e-03
REACTOME NEGATIVE REGULATORS OF RIG I MDA5 SIGNALING	0.81	1.61e-02

## LV931




**Figure 13: Cell types for LV931.**

**Table 11:** Pathways aligned to LV931 from the MultiPLIER models.

Pathway	AUC	FDR
MIPS SPLICEOSOME	0.63	3.13e-02
PID TGFBRPATHWAY	0.71	3.99e-02

## LV66




**Figure 14:** Cell types for LV66.

**Table 12:** Pathways aligned to LV66 from the MultiPLIER models.


Pathway	AUC	FDR
REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS	0.62	3.12e-04


## Agreement of consensus clustering partitions with the ensemble by number of clusters



**Figure 15:** Final selected partitions for follow-up analysis. From all consensus clustering partitions generated with  $k$  from 2 to 60, we selected those with a median adjusted Rand index (ARI) with the ensemble members greater than the 75th percentile.


## Cluster-specific and general transcriptional processes associated with disease





**Figure 16: Cluster-specific and general transcriptional processes associated with disease using novel LVs.** The plot shows a submatrix of  $\hat{M}$  for the main trait clusters at  $k=29$ , considering only LVs (rows) that are not aligned with any pathway. Standardized values from -6 (lighter color) to 21 (darker color).

## LV928



**Figure 17: Cell types for LV928.**

**Table 13:** Pathways aligned to LV928 from the MultiPLIER models.

<b>Pathway</b>	<b>AUC</b>	<b>FDR</b>
DMAP ERY3	0.81	1.16e-24
DMAP ERY4	0.78	2.49e-17


**Table 14:** Significant trait associations of LV928 in PhenomeXcan.

<b>Trait description</b>	<b>Sample size</b>	<b>Cases</b>	<b>Partition / cluster</b>	<b>FDR</b>
Mean spheroid cell volume	344,729		29 / 2	2.18e-46
Mean reticulocyte volume	344,728		29 / 2	4.08e-44
Mean corpuscular volume	350,473		29 / 2	5.57e-33
Red blood cell (erythrocyte) distribution width	350,473		29 / 23	7.62e-31
Reticulocyte percentage	344,728		29 / 4	2.12e-29
Reticulocyte count	344,729		29 / 4	6.88e-28
Reticulocyte Count	173,480		29 / 4	1.06e-23
Mean corpuscular haemoglobin	350,472		29 / 2	7.89e-23
High light scatter reticulocyte count	344,729		29 / 4	3.05e-21
Immature reticulocyte fraction	344,728		29 / 4	5.04e-21
High light scatter reticulocyte percentage	344,729		29 / 4	1.57e-16
Red blood cell (erythrocyte) count	350,475		29 / 5	2.53e-16
Red Blood Cell Count	173,480		29 / 5	2.62e-09
Haemoglobin concentration	350,474		29 / 5	1.25e-03
Haematocrit percentage	350,475		29 / 5	3.77e-03

**Table 15:** Significant trait associations of LV928 in eMERGE.

<b>Phecode</b>	<b>Trait description</b>	<b>Sample size</b>	<b>Cases</b>	<b>FDR</b>
250.24	Type 2 diabetes with neurological manifestations	43,236	2,963	1.44e-02
195	Cancer, suspected or other	50,040	2,250	2.42e-02
514.2	Solitary pulmonary nodule	50,389	2,270	4.65e-02

## LV30



**Figure 18:** Cell types for LV30.

**Table 16:** Pathways aligned to LV30 from the MultiPLIER models.

Pathway	AUC	FDR
DMAP ERY3	0.95	5.62e-52
DMAP ERY4	0.98	5.28e-51
DMAP ERY5	0.98	1.96e-49


**Table 17:** Significant trait associations of LV30 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
Mean reticulocyte volume	344,728		29 / 2	1.41e-51
Immature reticulocyte fraction	344,728		29 / 4	5.79e-40
Mean spheroid cell volume	344,729		29 / 2	3.26e-36
Mean corpuscular volume	350,473		29 / 2	3.18e-35
Reticulocyte percentage	344,728		29 / 4	1.41e-28
Mean corpuscular haemoglobin	350,472		29 / 2	3.72e-28
High light scatter reticulocyte count	344,729		29 / 4	8.20e-28
Reticulocyte count	344,729		29 / 4	2.13e-26
Reticulocyte Count	173,480		29 / 4	1.11e-24
High light scatter reticulocyte percentage	344,729		29 / 4	4.05e-22

**Table 18:** Significant trait associations of LV30 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
No significant associations				

**LV730**



**Figure 19: Cell types for LV730.**

**Table 19:** Pathways aligned to LV730 from the MultiPLIER models.

Pathway	AUC	FDR
DMAP MEGA2	0.82	2.64e-05


**Table 20:** Significant trait associations of LV730 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
Platelet distribution width	350,470		29 / 1	2.88e-13
Mean platelet (thrombocyte) volume	350,470		29 / 1	7.26e-13
Platelet count	350,474		29 / 1	1.24e-07
Platelet Count	173,480		29 / 1	1.21e-06
Platelet crit	350,471		29 / 1	1.38e-04

**Table 21:** Significant trait associations of LV730 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
No significant associations				

## LV598



**Figure 20: Cell types for LV598.**

**Table 22:** Pathways aligned to LV598 from the MultiPLIER models.

Pathway	AUC	FDR
PID SYNDÉCAN 1 PATHWAY	0.81	1.20e-02
REACTOME COLLAGEN FORMATION	0.77	1.89e-02


**Table 23:** Significant trait associations of LV598 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
6mm strong meridian (right)	66,256		29 / 10	3.21e-07
6mm weak meridian (right)	66,256		29 / 10	2.04e-06
6mm strong meridian (left)	65,551		29 / 10	2.44e-06
3mm strong meridian (left)	75,398		29 / 10	2.53e-06
6mm weak meridian (left)	65,551		29 / 10	1.20e-05
3mm weak meridian (left)	75,398		29 / 10	1.58e-05
3mm strong meridian (right)	75,410		29 / 10	2.95e-05
3mm weak meridian (right)	75,410		29 / 10	3.86e-05

**Table 24:** Significant trait associations of LV598 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
No significant associations				

## LV844



**Figure 21: Cell types for LV844.**

**Table 25:** Pathways aligned to LV844 from the MultiPLIER models.

Pathway	AUC	FDR
KEGG ANTIGEN PROCESSING AND PRESENTATION	0.80	1.35e-03

**Table 26:** Significant trait associations of LV844 in PhenomeXcan.


Trait description	Sample size	Cases	Partition / cluster	FDR
Rheumatoid Arthritis	80,799	19,234	29 / 26	1.20e-57
malabsorption/coeliac disease (self-reported)	361,141	1,587	29 / 8	1.25e-43
Coeliac disease	361,194	842	29 / 8	1.52e-41
Intestinal malabsorption (ICD10 K90)	361,194	922	29 / 8	5.28e-40
Started insulin within one year diagnosis of diabetes	16,415	1,999	29 / 13	7.77e-38
Systemic Lupus Erythematosus	23,210	7,219	29 / 26	6.45e-35
Age diabetes diagnosed	16,166		29 / 13	1.92e-34
Never eat: Wheat products	359,777	9,573	29 / 13	1.37e-31
hyperthyroidism (self-reported)	361,141	2,730	29 / 13	3.41e-30
Medication: insulin product	361,141	3,545	29 / 13	1.78e-25
Insulin medication (females)	193,148	1,476	29 / 13	2.79e-23
Insulin medication (males)	165,340	2,248	29 / 13	1.27e-20
hypothyroidism (self-reported)	361,141	17,574	29 / 13	3.35e-20
Medication: levothyroxine sodium	361,141	14,689	29 / 13	2.76e-19

Trait description	Sample size	Cases	Partition / cluster	FDR
psoriasis (self-reported)	361,141	4,192	29 / 13	6.74e-16

**Table 27:** Significant trait associations of LV844 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
714.1	Rheumatoid arthritis	49,453	2,541	1.53e-08
250.1	Type 1 diabetes	42,723	2,450	3.85e-08
714	Rheumatoid arthritis and other inflammatory polyarthropathies	50,215	3,303	1.02e-06
440	Atherosclerosis	47,471	4,993	6.73e-03
578.8	Hemorrhage of rectum and anus	47,545	1,991	6.73e-03
585.32	End stage renal disease	43,309	1,842	9.01e-03
440.2	Atherosclerosis of the extremities	45,524	3,046	1.09e-02
514.2	Solitary pulmonary nodule	50,389	2,270	1.39e-02
444	Arterial embolism and thrombosis	43,378	900	2.97e-02
440.22	Atherosclerosis of native arteries of the extremities with intermittent claudication	44,639	2,161	3.61e-02

## LV155



**Figure 22:** Cell types for LV155.

**Table 28:** Pathways aligned to LV155 from the MultiPLIER models.

Pathway	AUC	FDR
No pathways significantly enriched		


**Table 29:** Significant trait associations of LV155 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
hypothyroidism (self-reported)	361,141	17,574	29 / 13	1.65e-03
hyperthyroidism (self-reported)	361,141	2,730	29 / 13	1.03e-02
Medication: levothyroxine sodium	361,141	14,689	29 / 13	1.12e-02

**Table 30:** Trait associations of LV155 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
244.2	Acquired hypothyroidism	45,839	1,155	5.66e-02

## LV57



**Figure 23:** Cell types for LV57.

**Table 31:** Pathways aligned to LV57 from the MultiPLIER models.

Pathway	AUC	FDR
KEGG T CELL RECEPTOR SIGNALING PATHWAY	0.70	1.26e-03
SVM T cells CD4 memory activated	0.79	2.59e-03
IRIS CD4Tcell-Th2-restimulated12hour	0.78	7.57e-03
KEGG ALLOGRAFT REJECTION	1.00	1.09e-02
Custom Treg	0.98	1.37e-02

Pathway		AUC	FDR
PID NFAT TFPATHWAY		0.74	1.52e-02
IRIS MemoryTcell-RO-activated		0.70	2.87e-02


**Table 32:** Significant trait associations of LV57 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
hypothyroidism (self-reported)	361,141	17,574	29 / 13	7.21e-25
Medication: levothyroxine sodium	361,141	14,689	29 / 13	3.71e-23
hyperthyroidism (self-reported)	361,141	2,730	29 / 13	8.93e-07
Started insulin within one year diagnosis of diabetes	16,415	1,999	29 / 13	6.60e-05
Medication: insulin product	361,141	3,545	29 / 13	5.20e-04
Insulin medication (females)	193,148	1,476	29 / 13	9.40e-04
Insulin medication (males)	165,340	2,248	29 / 13	3.63e-03

**Table 33:** Significant trait associations of LV57 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
244	Hypothyroidism	54,404	9,720	7.66e-09
244.4	Hypothyroidism NOS	53,968	9,284	7.66e-09
279	Disorders involving the immune mechanism	56,771	3,309	1.07e-02
514.2	Solitary pulmonary nodule	50,389	2,270	2.62e-02
714	Rheumatoid arthritis and other inflammatory polyarthropathies	50,215	3,303	3.77e-02

## LV54



**Figure 24: Cell types for LV54.**

**Table 34:** Pathways aligned to LV54 from the MultiPLIER models.

Pathway	AUC	FDR
No pathways significantly enriched		

**Table 35:** Significant trait associations of LV54 in PhenomeXcan.


Trait description	Sample size	Cases	Partition / cluster	FDR
Intestinal malabsorption (ICD10 K90)	361,194	922	29 / 8	3.10e-25
Coeliac disease	361,194	842	29 / 8	4.78e-25
Never eat: Wheat products	359,777	9,573	29 / 13	3.93e-23
Systemic Lupus Erythematosus	23,210	7,219	29 / 26	8.16e-23
Started insulin within one year diagnosis of diabetes	16,415	1,999	29 / 13	2.57e-20
hyperthyroidism (self-reported)	361,141	2,730	29 / 13	6.70e-19
Medication: insulin product	361,141	3,545	29 / 13	3.62e-18
Age diabetes diagnosed	16,166		29 / 13	9.20e-18
malabsorption/coeliac disease (self-reported)	361,141	1,587	29 / 8	9.63e-15
Insulin medication (males)	165,340	2,248	29 / 13	6.01e-14
psoriasis (self-reported)	361,141	4,192	29 / 13	1.81e-13
Rheumatoid Arthritis	80,799	19,23 4	29 / 26	2.17e-13
Insulin medication (females)	193,148	1,476	29 / 13	2.61e-12
Medication: levothyroxine sodium	361,141	14,68 9	29 / 13	4.25e-10
hypothyroidism (self-reported)	361,141	17,57 4	29 / 13	2.49e-08

**Table 36:** Significant trait associations of LV54 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
250.1	Type 1 diabetes	42,723	2,450	1.69e-13
244	Hypothyroidism	54,404	9,720	1.01e-05
244.4	Hypothyroidism NOS	53,968	9,284	1.01e-05
695	Erythematous conditions	48,347	4,210	8.54e-05
714	Rheumatoid arthritis and other inflammatory polyarthropathies	50,215	3,303	6.58e-04
440	Atherosclerosis	47,471	4,993	1.90e-03
585	Renal failure	51,437	9,970	7.10e-03
585.33	Chronic Kidney Disease, Stage III	46,279	4,812	7.49e-03
585.32	End stage renal disease	43,309	1,842	7.49e-03
250.6	Polyneuropathy in diabetes	41,948	1,675	8.55e-03
250	Diabetes mellitus	52,531	12,25 8	1.02e-02

Phecode	Trait description	Sample size	Cases	FDR
285.2	Anemia of chronic disease	39,673	2,606	1.64e-02
502	Postinflammatory pulmonary fibrosis	42,396	1,723	1.77e-02
415.1	Acute pulmonary heart disease	49,887	1,857	1.88e-02
285.21	Anemia in chronic kidney disease	38,616	1,549	2.53e-02
585.3	Chronic renal failure [CKD]	49,204	7,737	2.62e-02
743	Osteoporosis, osteopenia and pathological fracture	55,165	11,990	2.87e-02
415.11	Pulmonary embolism and infarction, acute	49,867	1,837	3.04e-02
577	Diseases of pancreas	60,538	1,795	3.06e-02
585.1	Acute renal failure	46,803	5,336	3.23e-02
195	Cancer, suspected or other	50,040	2,250	3.27e-02
289.4	Lymphadenitis	47,564	3,078	3.67e-02
440.2	Atherosclerosis of the extremities	45,524	3,046	4.52e-02

## LV847



**Figure 25:** Cell types for LV847.

**Table 37:** Pathways aligned to LV847 from the MultiPLIER models.

Pathway	AUC	FDR
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS	0.74	1.86e-04
REACTOME MEIOTIC RECOMBINATION	0.78	3.60e-04
REACTOME RNA POL I TRANSCRIPTION	0.75	5.56e-04
REACTOME AMYLOIDS	0.76	2.17e-03

**Table 38:** Significant trait associations of LV847 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
Mean corpuscular haemoglobin	350,472		29 / 2	7.34e-73
Mean corpuscular volume	350,473		29 / 2	1.43e-50
Blood pressure medication (females)	193,148	33, 519	29 / 17	1.38e-18
Heart attack, angina, stroke or hypertension	360,420	253 ,56 5	29 / 17	2.92e-15
hypertension	360,420	97, 139	29 / 17	4.82e-14
hypertension (self-reported)	361,141	93, 560	29 / 17	1.02e-13
Medication: bendroflumethiazide	361,141	20, 196	29 / 17	1.06e-08
Mean spheroid cell volume	344,729		29 / 2	2.16e-08
Blood pressure medication (males)	165,340	40, 987	29 / 17	1.14e-07
Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones (females)	193,148	133 ,33 8	29 / 17	1.21e-06
Diastolic blood pressure, automated reading	340,162		29 / 17	2.93e-06
Medication for cholesterol, blood pressure or diabetes (males)	165,340	110 ,37 2	29 / 17	5.01e-06
Mean reticulocyte volume	344,728		29 / 2	8.38e-03


**Table 39:** Significant trait associations of LV847 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
585.32	End stage renal disease	43,309	1,84 2	3.11e-08
443	Peripheral vascular disease	47,867	5,38 9	4.13e-06
442.1	Aortic aneurysm	45,589	3,11 1	1.01e-05
411.3	Angina pectoris	43,503	4,38 2	4.28e-05
440.2	Atherosclerosis of the extremities	45,524	3,04 6	6.57e-05
415.11	Pulmonary embolism and infarction, acute	49,867	1,83 7	9.90e-05
416	Cardiomegaly	53,289	5,25 9	1.34e-04
415.1	Acute pulmonary heart disease	49,887	1,85 7	1.49e-04

Phecode	Trait description	Sample size	Cases	FDR
599.3	Dysuria	42,858	3,581	1.74e-04
585	Renal failure	51,437	9,970	3.90e-04
411	Ischemic Heart Disease	54,275	15,154	1.19e-03
531	Peptic ulcer (excl. esophageal)	59,472	1,561	2.26e-03
250.6	Polyneuropathy in diabetes	41,948	1,675	2.32e-03
443.9	Peripheral vascular disease, unspecified	46,926	4,448	2.40e-03
519	Other diseases of respiratory system, not elsewhere classified	56,909	2,056	2.43e-03
401.2	Hypertensive heart and/or renal disease	30,405	6,253	2.43e-03
411.8	Other chronic ischemic heart disease, unspecified	44,123	5,002	2.71e-03
440.22	Atherosclerosis of native arteries of the extremities with intermittent claudication	44,639	2,161	2.97e-03
401.22	Hypertensive chronic kidney disease	28,944	4,792	5.61e-03
514	Abnormal findings examination of lungs	54,668	6,549	6.96e-03
427.6	Premature beats	31,575	2,453	1.27e-02
585.1	Acute renal failure	46,803	5,336	1.39e-02
418	Nonspecific chest pain	51,082	17,765	1.39e-02
250.1	Type 1 diabetes	42,723	2,450	1.44e-02
285.21	Anemia in chronic kidney disease	38,616	1,549	1.82e-02
368	Visual disturbances	56,141	2,694	1.88e-02
427.5	Arrhythmia (cardiac) NOS	36,861	7,739	2.01e-02
687.1	Rash and other nonspecific skin eruption	47,039	4,964	2.15e-02
185	Cancer of prostate	52,630	2,815	2.31e-02
747	Cardiac and circulatory congenital anomalies	59,494	2,167	2.47e-02
444	Arterial embolism and thrombosis	43,378	900	2.53e-02

Pheco de	Trait description	Sample size	Cases	FDR
585.3	Chronic renal failure [CKD]	49,204	7,737	2.53e-02
440	Atherosclerosis	47,471	4,993	2.62e-02
591	Urinary tract infection	49,727	10,016	2.94e-02
411.1	Unstable angina (intermediate coronary syndrome)	41,763	2,642	3.06e-02
285.2	Anemia of chronic disease	39,673	2,606	3.06e-02
274.1	Gout	59,252	3,394	3.23e-02
585.34	Chronic Kidney Disease, Stage IV	43,322	1,855	3.84e-02
452	Other venous embolism and thrombosis	40,476	3,816	4.49e-02
427.12	Paroxysmal ventricular tachycardia	31,154	2,032	4.52e-02

## LV136



**Figure 26: Cell types for LV136.** Pulmonary microvascular endothelial cells were exposed to hypoxia for 24 hours or more [108];

**Table 40:** Pathways aligned to LV136 from the MultiPLIER models.

Pathway	AUC	FDR
PID INTEGRIN1 PATHWAY	0.88	9.35e-06
KEGG ECM RECEPTOR INTERACTION	0.80	7.29e-05

<b>Pathway</b>		<b>AUC</b>	<b>FDR</b>
REACTOME COLLAGEN FORMATION		0.87	2.00e-04
REACTOME MUSCLE CONTRACTION		0.75	1.49e-02


**Table 41:** Significant trait associations of LV136 in PhenomeXcan.

<b>Trait description</b>	<b>Sample size</b>	<b>Cases</b>	<b>Partition / cluster</b>	<b>FDR</b>
3mm strong meridian (right)	75,410		29 / 10	6.37e-11
6mm strong meridian (left)	65,551		29 / 10	1.53e-09
6mm strong meridian (right)	66,256		29 / 10	1.78e-09
3mm strong meridian (left)	75,398		29 / 10	9.90e-09
Coronary Artery Disease	184,305	60,80 1	29 / 11	1.26e-08
3mm weak meridian (right)	75,410		29 / 10	1.26e-08
6mm weak meridian (right)	66,256		29 / 10	2.41e-08
3mm weak meridian (left)	75,398		29 / 10	3.96e-08
6mm weak meridian (left)	65,551		29 / 10	9.31e-08
Coronary atherosclerosis	361,194	14,33 4	29 / 14	3.04e-06
Ischaemic heart disease (wide definition)	361,194	20,85 7	29 / 14	5.71e-06
Heart attack	360,420	8,288	29 / 14	2.36e-04
Myocardial infarction	361,194	7,018	29 / 14	5.20e-04
Acute myocardial infarction (ICD10 I21)	361,194	5,948	29 / 14	8.14e-04
heart attack/myocardial infarction (self-reported)	361,141	8,239	29 / 14	1.16e-03
Major coronary heart disease event	361,194	10,15 7	29 / 14	1.47e-02

**Table 42:** Trait associations of LV136 in eMERGE.

<b>Phecode</b>	<b>Trait description</b>	<b>Sample size</b>	<b>Cases</b>	<b>FDR</b>
747.1	Cardiac congenital anomalies	59,198	1,871	1.57e-01
411.4	Coronary atherosclerosis	52,836	13,715	1.60e-01

## LV93



**Figure 27: Cell types for LV93.**

**Table 43:** Pathways aligned to LV93 from the MultiPLIER models.

Pathway	AUC	FDR
No pathways significantly enriched		


**Table 44:** Significant trait associations of LV93 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
CH2DB NMR	24,154		29 / 16	5.91e-24
Reticulocyte Count	173,480		29 / 4	1.33e-14
High light scatter reticulocyte count	344,729		29 / 4	2.52e-13
Reticulocyte count	344,729		29 / 4	1.35e-12
Reticulocyte percentage	344,728		29 / 4	4.93e-11
High light scatter reticulocyte percentage	344,729		29 / 4	2.18e-10
Immature reticulocyte fraction	344,728		29 / 4	2.31e-08
Chronotype	128,266		29 / 16	9.73e-04
HDL Cholesterol NMR	19,270		29 / 16	2.41e-03

**Table 45:** Significant trait associations of LV93 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
208	Benign neoplasm of colon	55,694	8,597	1.39e-02
440.2	Atherosclerosis of the extremities	45,524	3,046	2.87e-02

## LV206



**Figure 28: Cell types for LV206.**

**Table 46:** Pathways aligned to LV206 from the MultiPLIER models.

Pathway	AUC	FDR
No pathways significantly enriched		


**Table 47:** Significant trait associations of LV206 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
CH2DB NMR	24,154		29 / 16	5.04e-21
HDL Cholesterol NMR	19,270		29 / 16	5.20e-03

**Table 48:** Significant trait associations of LV206 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
458	Hypotension	51,341	4,432	3.06e-02
286.9	Abnormal coagulation profile	48,006	800	3.39e-02
458.9	Hypotension NOS	50,150	3,241	3.58e-02
428.2	Heart failure NOS	48,178	3,584	3.71e-02

## LV260



**Figure 29: Cell types for LV260.**

**Table 49:** Pathways aligned to LV260 from the MultiPLIER models.

Pathway	AUC	FDR
No pathways significantly enriched		


**Table 50:** Significant trait associations of LV260 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
CH2DB NMR	24,154		29 / 16	4.35e-17
HDL Cholesterol NMR	19,270		29 / 16	1.88e-02

**Table 51:** Trait associations of LV260 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
427.6	Premature beats	31,575	2,453	7.90e-02

## LV21



**Figure 30: Cell types for LV21.**

**Table 52:** Pathways aligned to LV21 from the MultiPLIER models.

Pathway	AUC	FDR
No pathways significantly enriched		


**Table 53:** Significant trait associations of LV21 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
Alzheimers Disease	54,162	17,008	29 / 16	1.11e-19
LDL Cholesterol NMR	13,527		29 / 16	9.53e-05
Triglycerides NMR	21,559		29 / 16	1.74e-02

**Table 54:** Trait associations of LV21 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
573	Other disorders of liver	47,826	2,524	2.99e-02
577	Diseases of pancreas	60,538	1,795	5.51e-02

## LV5



**Figure 31: Cell types for LV5.**

**Table 55:** Pathways aligned to LV5 from the MultiPLIER models.

Pathway	AUC	FDR
No pathways significantly enriched		

**Table 56:** Significant trait associations of LV5 in PhenomeXcan.


Trait description	Sample size	Cases	Partition / cluster	FDR
LDL Cholesterol NMR	13,527		29 / 16	1.44e-04
Triglycerides NMR	21,559		29 / 16	4.03e-04
Alzheimers Disease	54,162	17,00 8	29 / 16	2.47e-03
Ever had prolonged feelings of sadness or depression	117,763	64,37 4	29 / 27	6.92e-03
Medication for depression	117,763	28,35 1	29 / 27	8.24e-03
Recent feelings of depression	117,656		29 / 27	1.05e-02
Ever contemplated self-harm	117,610		29 / 27	1.50e-02
Recent lack of interest or pleasure in doing things	117,757		29 / 27	1.65e-02
Amount of alcohol drunk on a typical drinking day	108,256		29 / 27	2.77e-02
Ever sought or received professional help for mental distress	117,677	46,02 0	29 / 27	3.08e-02
General happiness	117,442		29 / 27	3.73e-02
Depression (diagnosed by a professional)	117,782	25,08 7	29 / 27	4.03e-02

**Table 57:** Trait associations of LV5 in eMERGE.

<b>Phecode</b>	<b>Trait description</b>	<b>Sample size</b>	<b>Cases</b>	<b>FDR</b>
241	Nontoxic nodular goiter	47,842	3,158	1.92e-02

Phecode	Trait description	Sample size	Cases	FDR
241.1	Nontoxic uninodular goiter	47,125	2,441	6.84e-02

## LV434



**Figure 32: Cell types for LV434.** HEK293 is a cell line derived from human embryonic kidney cells; 3T3 is a cell line derived from mouse embryonic fibroblasts.

**Table 58:** Pathways aligned to LV434 from the MultiPLIER models.

Pathway	AUC	FDR
No pathways significantly enriched		

**Table 59:** Significant trait associations of LV434 in PhenomeXcan.

Trait description	Sample size	Cases	Partition / cluster	FDR
Attention Deficit Hyperactivity Disorder	53,293	19,099	29 / 21	5.62e-03

**Table 60:** Significant trait associations of LV434 in eMERGE.

Phecode	Trait description	Sample size	Cases	FDR
722	Intervertebral disc disorders	47,659	7,458	1.44e-02
721	Spondylosis and allied disorders	47,517	7,316	1.64e-02
250.4	Abnormal glucose	45,220	4,947	2.23e-02
721.1	Spondylosis without myelopathy	47,315	7,114	2.66e-02
720	Spinal stenosis	44,807	4,606	3.99e-02